




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|---|
| (51) International Patent Classification ⁵ : C12N 15/12, 5/10, C12Q 1/68, C07K 13/00, G01N 33/68, C12P 21/08 | | A2 | (11) International Publication Number: WO 94/20617 |
| | | | (43) International Publication Date: 15 September 1994 (15.09.94) |
| (21) International Application Number: PCT/US94/02447 | | (74) Agent: REITER, Stephen, E.; Pretty, Schroeder, Brueggemann & Clark, Suite 2000, 444 South Flower Street, Los Angeles, CA 90071 (US). | |
| (22) International Filing Date: 8 March 1994 (08.03.94) | | | |
| (30) Priority Data: 08/028,031 8 March 1993 (08.03.93) US | | (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (60) Parent Application or Grant (63) Related by Continuation US 08/028,031 (CIP) Filed on 8 March 1993 (08.03.93) | | | |
| (71) Applicant (for all designated States except US): THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INCORPORATED [US/US]; Suite 300, 505 Coast Boulevard South, La Jolla, CA 92037-4641 (US). | | Published Without international search report and to be republished upon receipt of that report. | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): ELLIOTT, Kathryn, J. [US/US]; 3854 Baker Street, San Diego, CA 92117 (US). ELLIS, Steven, B. [US/US]; 8939 Oviedo Street, San Diego, 92129 (US). HARPOLD, Michael, M. [US/US]; 15630 Creek Hills Road, El Cajon, CA 92021 (US). | | | |

(54) Title: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME

(57) Abstract

Nucleic acids encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing said nucleic acids, methods for producing alpha and beta subunits and recombinant (i.e., isolated or substantially pure) alpha subunits (specifically α_4 and α_7) and beta subunits (specifically β_4) are provided. In addition, combinations of subunits (i.e., α_1 , α_2 , α_3 , α_4 , and/or α_7 subunits in combination with β_4 subunits; or β_2 , β_3 and/or β_4 subunits in combination with α_4 and/or α_7 subunits) are provided.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR
COMPOSITIONS AND METHODS EMPLOYING SAME

This invention relates to nucleic acids encoding human neuronal nicotinic acetylcholine receptor protein subunits, as well as the proteins themselves. In particular, human neuronal nicotinic acetylcholine
5 receptor α -subunit-encoding nucleic acids, α -subunit proteins, β -subunit-encoding nucleic acids, β -subunit proteins, and combinations thereof are provided.

BACKGROUND OF THE INVENTION

Ligand-gated ion channels provide a means for
10 communication between cells of the central nervous system. These channels convert a signal (e.g., a chemical referred to as a neurotransmitter) that is released by one cell into an electrical signal that propagates along a target cell membrane. A variety of
15 neurotransmitters and neurotransmitter receptors exist in the central and peripheral nervous systems. Five families of ligand-gated receptors, including the nicotinic acetylcholine receptors (NACHRs) of neuromuscular and neuronal origins, have been identified
20 (Stroud et al. (1990) Biochemistry 29:11009-11023). There is, however, little understanding of the manner in which the variety of receptors generates different responses to neurotransmitters or to other modulating ligands in different regions of the nervous system.

25 The nicotinic acetylcholine receptors (NACHRs) are multisubunit protein of neuromuscular and neuronal origins. These receptors form ligand-gated ion channels that mediate synaptic transmission between nerve and muscle and between neurons upon interaction with the
30 neurotransmitter acetylcholine (ACh). Since various nicotinic acetylcholine receptor (NACHR) subunits exist, a variety of NACHR compositions (i.e., combinations of

subunits) exist. The different NACHR compositions exhibit different specificities for various ligands and are thereby pharmacologically distinguishable. Thus, the nicotinic acetylcholine receptors expressed at the vertebrate neuromuscular junction in vertebrate sympathetic ganglia and in the vertebrate central nervous system have been distinguished on the basis of the effects of various ligands that bind to different NACHR compositions. For example, the elapid α -neurotoxins that block activation of nicotinic acetylcholine receptors at the neuromuscular junction do not block activation of some neuronal nicotinic acetylcholine receptors that are expressed on several different neuron-derived cell lines.

Muscle NACHR is a glycoprotein composed of five subunits with the stoichiometry $\alpha_2\beta(\gamma \text{ or } \epsilon)\delta$. Each of the subunits has a mass of about 50-60 kilodaltons (kd) and is encoded by a different gene. The $\alpha_2\beta(\gamma \text{ or } \epsilon)\delta$ complex forms functional receptors containing two ligand binding sites and a ligand-gated transmembrane channel. Upon interaction with a cholinergic agonist, muscle nicotinic AChRs conduct sodium ions. The influx of sodium ions rapidly short-circuits the normal ionic gradient maintained across the plasma membrane, thereby depolarizing the membrane. By reducing the potential difference across the membrane, a chemical signal is transduced into an electrical signal that signals muscle contraction at the neuromuscular junction.

Functional muscle nicotinic acetylcholine receptors have been formed with $\alpha\beta\delta\gamma$ subunits, $\alpha\beta\gamma$ subunits, $\alpha\beta^+$ subunits, $\alpha\delta\gamma$ subunits or $\alpha\delta$ subunits, but not with only one subunit (see e.g., Kurosaki et al. (1987) FEBS Lett. 214: 253-258; Camacho et al. (1993) J. Neuroscience 13:605-613). In contrast, functional neuronal AChRs (nAChRs) can be formed from α subunits alone or combinations of α and β subunits. Th larger α

subunit is generally believed to be the ACh-binding subunit and the lower molecular weight β subunit is generally believed to be the structural subunit, although it has not been definitively demonstrated that the β subunit does not have the ability to bind ACh. Each of the subunits which participate in the formation of a functional ion channel are, to the extent they contribute to the structure of the resulting channel, "structural" subunits, regardless of their ability (or inability) to bind ACh. Neuronal AChRs (nAChRs), which are also ligand-gated ion channels, are expressed in ganglia of the autonomic nervous system and in the central nervous system (where they mediate signal transmission), in post-synaptic locations (where they modulate transmission), and in pre- and extra-synaptic locations (where they may have additional functions).

Nucleic acids encoding NACHRs has been isolated from several sources. Based on the information available from such work, it has been evident for some time that NACHRs expressed in muscle, in autonomic ganglia, and in the central nervous system are functionally diverse. This functional diversity could be due, at least in part, to the large number of different NACHR subunits which exist. There is an incomplete understanding, however, of how (and which) NACHR subunits combine to generate unique NACHR subtypes, particularly in neuronal cells. Indeed, there is evidence that only certain NACHR subtypes may be involved in diseases such as Alzheimer's disease. Moreover, it is not clear whether NACHRs from analogous tissues or cell types are similar across species.

Accordingly, there is a need for the isolation and characterization of nucleic acids encoding each human neuronal NACHR subunit, recombinant cells containing such subunits and receptors prepared therefrom. In order to study the function of human neuronal AChRs and to obtain

disease-specific pharmacologically active agents, there is also a need to obtain isolated (preferably purified) human neuronal nicotinic AChRs, and isolated (preferably purified) human neuronal nicotinic AChR subunits. In addition, there is also a need to develop assays to identify such pharmacologically active agents.

The availability of such nucleic acids, cells, receptor subunits and receptor compositions will eliminate the uncertainty of speculating as to human nNACHR structure and function based on predictions drawn from non-human nNACHR data, or human or non-human muscle or ganglia NACHR data.

Therefore, it is an object herein to isolate and characterize nucleic acids encoding subunits of human neuronal nicotinic acetylcholine receptors. It is also an object herein to provide methods for recombinant production of human neuronal nicotinic acetylcholine receptor subunits. It is also an object herein to provide purified receptor subunits and to provide methods for screening compounds to identify compounds that modulate the activity of human neuronal AChRs.

These and other objects will become apparent to those of skill in the art upon further study of the specification and claims.

25

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided isolated nucleic acids encoding novel human alpha and beta subunits of neuronal NACHRs. In particular, isolated DNA encoding human α_4 , α_7 , and β_4 subunits of neuronal NACHRs are provided. Messenger RNA and polypeptides encoded by the above-described nucleic acids are also provided.

Further in accordance with the present invention, there are provided recombinant human neuronal nicotinic AChR subunits, including α_4 , α_7 , and β_4 subunits, as well as methods for the production thereof.

5 In addition, recombinant human neuronal nicotinic acetylcholine receptors containing at least one human neuronal nicotinic AChR subunit are also provided, as well as methods for the production thereof. Further provided are recombinant neuronal nicotinic AChRs that
10 contain a mixture of one or more NACHR subunits encoded by a host cell, and one or more nNACHR subunits encoded by heterologous DNA or RNA (i.e., DNA or RNA as described herein that has been introduced into the host cell), as well as methods for the production thereof.

15 Plasmids containing DNA encoding the above-described subunits are also provided. Recombinant cells containing the above-described DNA, mRNA or plasmids are also provided herein. Such cells are useful, for example, for replicating DNA, for producing human NACHR
20 subunits and recombinant receptors, and for producing cells that express receptors containing one or more human subunits.

Also provided in accordance with the present invention are methods for identifying cells that express
25 functional nicotinic acetylcholine receptors. Methods for identifying compounds which modulate the activity of NACHRs are also provided.

The DNA, mRNA, vectors, receptor subunits, receptor subunit combinations and cells provided herein
30 permit production of selected neuronal nicotinic AChR subunits and specific combinations thereof, as well as antibodies to said receptor subunits. This provides a means to prepare synthetic or recombinant receptors and receptor subunits that are substantially free of

contamination from many other receptor proteins whose presence can interfere with analysis of a single NACHR subunit. The availability of desired receptor subunits makes it possible to observe the effect of a drug
5 substance on a particular receptor subtype and to thereby perform initial *in vitro* screening of the drug substance in a test system that is specific for humans and specific for a human neuronal nicotinic AChR subtype.

The availability of subunit-specific antibodies
10 makes possible the application of the technique of immunohistochemistry to monitor the distribution and expression density of various subunits (e.g., in normal vs diseased brain tissue). Such antibodies could also be employed for diagnostic and therapeutic applications.

15 The ability to screen drug substances *in vitro* to determine the effect of the drug on specific receptor compositions should permit the development and screening of receptor subtype-specific or disease-specific drugs. Also, testing of single receptor subunits or specific
20 receptor subunit combinations with a variety of potential agonists or antagonists provides additional information with respect to the function and activity of the individual subunits and should lead to the identification and design of compounds that are capable of very specific
25 interaction with one or more receptor subtypes. The resulting drugs should exhibit fewer unwanted side effects than drugs identified by screening with cells that express a variety of subtypes.

Further in relation to drug development and
30 therapeutic treatment of various disease states, the availability of nucleic acids encoding human nNACHR subunits enables identification of any alterations in such genes (e.g., mutations) which may correlate with the occurrence of certain disease states. In addition, the

creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA sequences which can then be introduced into laboratory animals or *in vitro* assay systems to determine the effects thereof.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 presents a restriction map of two pCMV promoter-based vectors, pCMV-T7-2 and pCMV-T7-3.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have isolated and characterized nucleic acids encoding novel human alpha and beta subunits of neuronal NACHRs. Specifically, isolated DNAs encoding human α_4 , α_7 , and β_4 subunits of neuronal NACHRs are described herein.

Recombinant messenger RNA (mRNA) and recombinant polypeptides encoded by the above-described nucleic acids are also provided.

As used herein, isolated (or substantially pure) as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been separated from their *in vivo* cellular environments through the efforts of human beings. Thus as used herein, isolated (or substantially pure) DNA refers to DNAs purified according to standard techniques employed by those skilled in the art (see, e.g., Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

Similarly, as used herein, "recombinant" as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have

been prepared by the efforts of human beings, e.g., by cloning, recombinant expression, and the like. Thus as used herein, recombinant proteins, for example, refers to proteins produced by a recombinant host, expressing
5 nucleic acidss which have been added to that host through the efforts of human beings.

As used herein, a human alpha subunit gene is a gene that encodes an alpha subunit of a human neuronal nicotinic acetylcholine receptor. The alpha subunit is a
10 subunit of the NACHR to which ACh binds. Assignment of the name "alpha" to a putative nNACHR subunit, according to Deneris et al. [Tips (1991) 12:34-40] is based on the conservation of adjacent cysteine residues in the presumed extracellular domain of the subunit that are the
15 homologues of cysteines 192 and 193 of the *Torpedo* alpha subunit (see Noda et al. (1982) *Nature* 299:793-797). As used herein, an alpha subunit refers to a human nNACHR subunit that is encoded by nucleic acids that hybridizes under high stringency conditions to at least one of the
20 nNACHR alpha subunit-encoding nucleic acidss (or deposited clones) disclosed herein. An alpha subunit also binds to ACh under physiological conditions and at physiological concentrations and, in the optional presence of a beta subunit (i.e., some alpha subunits are
25 functional alone, while others require the presence of a beta subunit), generally forms a functional AChR as assessed by methods described herein or known to those of skill in this art.

Also contemplated are alpha subunits encoded by
30 nucleic acids that encode alpha subunits as defined above, but that by virtue of degeneracy of the genetic code do not necessarily hybridize to the disclosed nucleic acids or deposited clones under specified hybridization conditions. Such subunits also participate
35 in the formation of a functional receptor, as assessed by

the methods described herein or known to those of skill in the art, generally with one or more beta subunits. Typically, unless an alpha subunit is encoded by RNA that arises from alternative splicing (i.e., a splice variant), alpha-encoding nucleic acids and the alpha subunit encoded thereby share substantial sequence homology with at least one of the alpha subunit nucleic acidss (and proteins encoded thereby) described or deposited herein. It is understood that DNA or RNA encoding a splice variant may overall share less than 90% homology with the DNA or RNA provided herein, but include regions of nearly 100% homology to a DNA fragment or deposited clone described herein, and encode an open reading frame that includes start and stop codons and encodes a functional alpha subunit.

As used herein, a splice variant refers to variant NACHR subunit-encoding nucleic acid(s) produced by differential processing of primary transcript(s) of genomic DNA, resulting in the production of more than one type of mRNA. cDNA derived from differentially processed genomic DNA will encode NACHR subunits that have regions of complete amino acid identity and regions having different amino acid sequences. Thus, the same genomic sequence can lead to the production of multiple, related mRNAs and proteins. Both the resulting mRNAs and proteins are referred to herein as "splice variants".

Stringency of hybridization is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (T_m) of the hybrids. T_m can be approximated by the formula:

$$81.5^{\circ}\text{C} - 16.6(\log_{10}[\text{Na}^{+}]) + 0.41(\%G+C) - 600/L,$$

where l is the length of the hybrids in nucleotides. T_m decreases approximately 1-1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and

5 temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions. Thus, as used herein:

10 (1) HIGH STRINGENCY refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C (i.e., if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein). High stringency conditions can be provided, for example, by hybridization in 50%
15 formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C;

(2) MODERATE STRINGENCY refers to conditions equivalent to hybridization in 50%
25 formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 65°C; and

(3) LOW STRINGENCY refers to conditions equivalent to hybridization in 10%
30 formamide, 5X Denhardt's solution, 6X SSPE, 0.2% SDS, followed by washing in 1X SSPE, 0.2% SDS, at 50°C.

It is understood that these conditions may be duplicated using a variety of buffers and temperatures and that they are not necessarily precise.

Denhardt's solution and SSPE (see, e.g.,
5 Sambrook, Fritsch, and Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989) are well known to those of skill in the art as are other suitable hybridization buffers. For example, SSPE is pH 7.4 phosphate-buffered 0.18M NaCl. SSPE can be
10 prepared, for example, as a 20X stock solution by dissolving 175.3 g of NaCl, 27.6 g of NaH_2PO_4 and 7.4 g EDTA in 800 ml of water, adjusting the pH to 7.4, and then adding water to 1 liter. Denhardt's solution (see, Denhardt (1966) Biochem. Biophys. Res. Commun. 23:641)
15 can be prepared, for example, as a 50X stock solution by mixing 5 g Ficoll (Type 400, Pharmacia LKB Biotechnology, INC., Piscataway NJ), 5 g of polyvinylpyrrolidone, 5 g bovine serum albumin (Fraction V; Sigma, St. Louis MO) water to 500 ml and filtering to remove particulate
20 matter.

The phrase "substantial sequence homology" is used herein in reference to the nucleotide sequence of DNA, the ribonucleotide sequence of RNA, or the amino acid sequence of protein, that has slight and non-
25 consequential sequence variations from the actual sequences disclosed herein. Species having substantial sequence homology are considered to be equivalent to the disclosed sequences and as such are within the scope of the appended claims. In this regard, "slight and non-
30 consequential sequence variations" mean that "homologous" sequences, i.e., sequences that have substantial homology with the DNA, RNA, or proteins disclosed and claimed herein, are functionally equivalent to the sequences disclosed and claimed herein. Functionally equivalent
35 sequences will function in substantially the same manner

to produce substantially the same compositions as the nucleic acid and amino acid compositions disclosed and claimed herein. In particular, functionally equivalent nucleic acids encode proteins that are the same as those disclosed herein or that have conservative amino acid variations, such as substitution of a non-polar residue for another non-polar residue or a charged residue for a similarly charged residue. These changes include those recognized by those of skill in the art as those that do not substantially alter the tertiary structure of the protein.

In practice, the term substantially the same sequence means that DNA or RNA encoding two proteins hybridize under conditions of high stringency and encode proteins that have the same sequence of amino acids or have changes in sequence that do not alter their structure or function. As used herein, substantially identical sequences of nucleotides share at least about 90% identity, and substantially identical amino acid sequences share more than 95% amino acid identity. It is recognized, however, that proteins (and DNA or mRNA encoding such proteins) containing less than the above-described level of homology arising as splice variants or that are modified by conservative amino acid substitutions (or substitution of degenerate codons) are contemplated to be within the scope of the present invention.

As used herein, " α_4 subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example

said DNA may encode the amino acid sequence set forth in SEQ. ID No. 6, or

said DNA may encode the amino acid sequence encoded by clone HnAChR α 4.2, deposited under ATCC Accession No. 69239, or

the 5' nucleotides of said DNA may encode the amino acid sequence encoded by clone HnAChR α 4.1, deposited under ATCC Accession No. 69152.

Presently preferred α_4 -encoding DNAs can be characterized as follows

said DNA may hybridize to the coding sequence set forth in SEQ. ID No. 5 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 173-2056) under high stringency conditions, or

said DNA may hybridize under high stringency conditions to the sequence (preferably to substantially the entire sequence) of the α_4 -encoding insert of clone HnAChR α 4.2, deposited under ATCC Accession No. 69239, or

the 5' nucleotides of said DNA may hybridize under high stringency conditions to the sequence of the α_4 -encoding insert of clone HnAChR α 4.1, deposited under ATCC Accession No. 69152.

Especially preferred α_4 -encoding DNAs of the invention are characterized as follows

DNA having substantially the same nucleotide sequence as the coding region set forth in SEQ. ID No. 5 (i.e., nucleotides 173-2056 thereof), or

DNA having substantially the same nucleotide sequence as the α_4 -encoding insert of clone HnAChR α 4.2, deposited under ATCC Accession No. 69239, or

the 5' nucleotides of said DNA have substantially the same sequence as the α_4 -encoding insert of clone HnAChR α 4.1, deposited under ATCC Accession No. 69152.

Typically, unless an α_4 subunit arises as a splice variant, α_4 -encoding DNA will share substantial

sequence homology (i.e., greater than about 90%), with the α_4 DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100% homology to the above-described DNAs.

As used herein, " α_7 subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example, the nucleotides of said DNA may encode the amino acid sequence set forth in SEQ. ID No. 8. Presently preferred α_7 -encoding DNAs can be characterized as DNA which hybridizes under high stringency conditions to the coding sequence set forth in SEQ. ID No. 7 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 73-1581). Especially preferred α_7 -encoding DNAs of the invention are characterized as having substantially the same nucleotide sequence as the coding sequence set forth in SEQ. ID No. 7 (i.e., nucleotides 73-1581 thereof).

Typically, unless an α_7 subunit arises as a splice variant, α_7 -encoding DNA will share substantial sequence homology (greater than about 90%) with the α_7 DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such DNA would include regions of nearly 100% homology to the above-described DNA.

The α_7 subunits derived from the above-described DNA are expected to bind to the neurotoxin, α -bungarotoxin (α -bgtx). The activity of AChRs that contain α_7 subunits should be inhibited upon interaction with α -bgtx. Amino acid residues 210 through 217, as set forth in SEQ ID No. 8, are believed to be important

elements in the binding of α -bgtx (see, for example, Chargeaux et al. (1992) 13:299-301).

As used herein, a human beta subunit gene is a gene that encodes a beta subunit of a human neuronal
5 nicotinic acetylcholine receptor. Assignment of the name "beta" to a putative nNACHR subunit, according to Deneris et al. supra, is based on the lack of adjacent cysteine residues (which are characteristic of alpha subunits). The beta subunit is frequently referred to as the
10 structural NACHR subunit (although it is possible that beta subunits also have ACh binding properties). Combination of beta subunit(s) with appropriate alpha subunit(s) leads to the formation of a functional receptor. As used herein, a beta subunit refers to a
15 nNACHR subunit that is encoded by DNA that hybridizes under high stringency conditions to at least one of the nNACHR-encoding DNAs (or deposited clones) disclosed herein. A beta subunit forms a functional NACHR, as assessed by methods described herein or known to those of
20 skill in this art, with appropriate alpha subunit(s).

Also contemplated are beta subunits encoded by DNAs that encode beta subunits as defined above, but that by virtue of degeneracy of the genetic code do not necessarily hybridize to the disclosed DNA or deposited
25 clones under the specified hybridization conditions. Such subunits also form functional receptors, as assessed by the methods described herein or known to those of skill in the art, in combination with appropriate alpha subunit(s). Typically, unless a beta subunit is encoded
30 by RNA that arises as a splice variant, beta-encoding DNA and the beta subunit encoded thereby share substantial sequence homology with the beta-encoding DNA and beta subunit protein described herein. It is understood that DNA or RNA encoding a splice variant may share less than
35 90% overall homology with the DNA or RNA provided herein,

but such DNA will include regions of nearly 100% homology to the DNA described herein.

As used herein, " β_4 subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example, the nucleotides of said DNA may encode the amino acid sequence set forth in SEQ. ID No. 12. Presently preferred β_4 -encoding DNAs can be characterized as DNA which hybridizes under high stringency conditions to the coding sequence set forth in SEQ. ID No. 11 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 87-1583). Especially preferred β_4 -encoding DNAs of the invention are characterized as having substantially the same nucleotide sequence as set forth in SEQ. ID No. 11.

Typically, unless a β_4 subunit arises as a splice variant, β_4 -encoding DNA will share substantial sequence homology (greater than about 90%) with the β_4 DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such DNA would include regions of nearly 100% homology to the above-described DNA.

DNA encoding human neuronal nicotinic AChR alpha and beta subunits may be isolated by screening suitable human cDNA or human genomic libraries under suitable hybridization conditions with DNA disclosed herein (including nucleotides derived from any of SEQ ID Nos. 5, 7 or 11, or with any of the deposited clones referred to herein (e.g., ATCC accession no. 69239 or 69152)). Suitable libraries can be prepared from neuronal tissue samples, hippocampus tissue, or cell lines, such as the human neuroblastoma cell line IMR32 (ATCC Accession No. CCL127), and the like. The library is

preferably screened with a portion of DNA including the entire subunit-encoding sequence thereof, or the library may be screened with a suitable probe.

- As used herein, a probe is single-stranded DNA
- 5 or RNA that has a sequence of nucleotides that includes at least 14 contiguous bases that are the same as (or the complement of) any 14 bases set forth in any of SEQ ID Nos. 1, 3, 5, 7, 9, or 11, or in the subunit encoding DNA in any of the deposited clones described herein (e.g.,
- 10 ATCC accession no. 69239 or 69152). Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode transmembrane domains, sequences predicted to encode the cytoplasmic loop, signal sequences, acetylcholine (ACh)
- 15 and α -bungarotoxin (α -bgtx) binding sites, and the like. Amino acids 210-220 are typically involved in ACh and α -bgtx binding. The approximate amino acid residues which are predicted to comprise such regions for other preferred probes are set forth in the following table:

| <u>Subunit</u> | <u>Signal Sequence</u> | <u>TMD1*</u> | <u>TMD2</u> | <u>TMD3</u> | <u>TMD4</u> | <u>Cytoplasmic Loop</u> |
|----------------|------------------------|--------------|-------------|-------------|-------------|-------------------------|
| α_2 | 1-55 | 264-289 | 297-320 | 326-350 | 444-515 | 351-443 |
| α_3 | 1-30 | 240-265 | 273-296 | 302-326 | 459-480 | 327-458 |
| α_4 | 1-33 | 241-269 | 275-289 | 303-330 | 593-618 | 594-617 |
| α_7 | 1-23 | 229-256 | 262-284 | 290-317 | 462-487 | 318-461 |
| β_2 | 1-25 | 234-259 | 267-288 | 295-320 | 453-477 | 321-452 |
| β_4 | 1-23 | 234-258 | 264-285 | 290-319 | 454-478 | 320-453 |

* TMD = transmembrane domain

Alternatively, portions of the DNA can be used as primers to amplify selected fragments in a particular library.

After screening the library, positive clones are identified by detecting a hybridization signal; the identified clones are characterized by restriction enzyme mapping and/or DNA sequence analysis, and then examined, by comparison with the sequences set forth herein or with the deposited clones described herein, to ascertain whether they include DNA encoding a complete alpha or beta subunit. If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If desired, the library can be rescreened with positive clones until overlapping clones that encode an entire alpha or beta subunit are obtained. If the library is a cDNA library, then the overlapping clones will include an open reading frame. If the library is genomic, then the overlapping clones may include exons and introns. In both instances, complete clones may be identified by comparison with the DNA and encoded proteins provided herein.

Complementary DNA clones encoding various human nNACHR alpha and beta subunits have been isolated. Each subunit appears to be encoded by a different gene. The DNA clones provided herein may be used to isolate genomic clones encoding each subunit and to isolate any splice variants by screening libraries prepared from different neural tissues. Nucleic acid amplification techniques, which are well known in the art, can be used to locate splice variants of human NACHR subunits. This is accomplished by employing oligonucleotides based on DNA sequences surrounding divergent sequence(s) as primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal the existence of splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization

can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts encoding human NACHR subunits.

It has been found that not all subunits are expressed in all neural tissues or in all portions of the brain. Thus, in order to isolate cDNA encoding particular subunits or splice variants of such subunits, it is preferable to screen libraries prepared from different neuronal or neural tissues. Preferred libraries for obtaining DNA encoding each subunit include: hippocampus to isolate human α_4 - and α_5 -encoding DNA; IMR32 (human neuroblastoma cells; ATCC Accession No. CCL127) to isolate human α_3 -, α_5 -, α_7 - and β_4 -encoding DNA, thalamus to isolate α_2 and β_2 -encoding DNA; and the like.

It appears that the distribution of expression of human neuronal nicotinic AChRs differs from the distribution of such receptors in rat. For example, RNA encoding the rat α_4 subunit is abundant in rat thalamus, but is not abundant in rat hippocampus (see, e.g., Wada et al. (1989) J. Comp. Neurol 284:314-335). No α_4 -encoding clones could be obtained, however, from a human thalamus library. Instead, human α_4 clones were ultimately obtained from a human hippocampus library. Thus, the distribution of α_4 nNACHR subunit in humans and rats appears to be quite different.

Rat α_3 subunit appears to be a CNS-associated subunit that is abundantly expressed in the thalamus and weakly expressed in the brain stem (see, e.g., Boulter et al. (1986) Nature 319:368-374; Boulter et al. (1987) Proc. Natl. Acad. Sci. USA 84:7763-7767; and Wada et al. (1989) J. Comp. Neurol 284:314-335). In efforts to clone DNA encoding the human nicotinic AChR α_3 subunit, however, several human libraries, including a thalamus library, were unsuccessfully screened. Surprisingly, clones

encoding human α_3 subunit were ultimately obtained from a brain stem library and from IMR32 cells that reportedly express few, if any, functional nicotinic acetylcholine receptors (see, e.g., Gotti et al. ((1986) Biochem.

- 5 Biophys. Res. Commun. 137: 1141-1147, and Clementi et al. (1986) J. Neurochem. 47: 291-297).

- Rat α_7 subunit transcript reportedly is abundantly expressed in the hippocampus (see Seguela et al. (1993) J. Neurosci. 13:596-604). Efforts to clone
- 10 DNA encoding a human α_7 subunit from a human hippocampus library (1×10^6 recombinants) were unsuccessful. Surprisingly, clones encoding a human NACHR α_7 subunit were ultimately obtained from an IMR32 cell cDNA library.

- The above-described nucleotide sequences can be
- 15 incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are well within the
- 20 level of skill of the art.

- As used herein, heterologous or foreign DNA and RNA are used interchangeably and refer to DNA or RNA that does not occur naturally as part of the genome of the cell in which it is present, or to DNA or RNA which is
- 25 found in a location or locations in the genome that differ from that in which it occurs in nature. Typically, heterologous or foreign DNA and RNA refers to DNA or RNA that is not endogenous to the host cell and has been artificially introduced into the cell. Examples
- 30 of heterologous DNA include DNA that encodes a human neuronal nicotinic AChR subunit, DNA that encodes RNA or proteins that mediate or alter expression of endogenous DNA by affecting transcription, translation, or other regulatable biochemical processes, and the like. The

cell that expresses heterologous DNA may contain DNA encoding the same or different expression products. Heterologous DNA need not be expressed and may be integrated into the host cell genome or maintained
5 episomally.

An expression vector includes vectors capable of expressing DNAs that are operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments.
10 Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned nucleic acids. Appropriate expression vectors are
15 well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. Presently preferred plasmids for expression of invention AChR
20 subunits in eukaryotic host cells, particularly mammalian cells, include cytomegalovirus (CMV) promoter-containing vectors such as pCMV, pCDNA1, and the like, as well as MMTV promoter-containing vectors, such as pMAMneo, and the like.

25 As used herein, a promoter region refers to a segment of DNA that controls transcription of DNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription
30 initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be *cis* acting or may be
35 responsive to *trans* acting factors. Promoters, depending

upon the nature of the regulation, may be constitutive or regulated. Exemplary promoters contemplated for use in the practice of the present invention include the SV40 early promoter, the cytomegalovirus (CMV) promoter, the
5 mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.

As used herein, the term "operatively linked" refers to the functional relationship of nucleic acids
10 with regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of nucleic acids to a promoter refers to the physical and functional
15 relationship between the nucleic acids and the promoter such that the transcription of such nucleic acids is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the nucleic acids. In order to optimize expression and/or *in*
20 *vitro* transcription, it may be necessary to remove or alter 5' and/or 3' untranslated portions of the clones to remove extra, potential alternative translation initiation (i.e., start) codons or other sequences that interfere with or reduce expression, either at the level
25 of transcription or translation. Alternatively, consensus ribosome binding sites (see, for example, Kozak (1991) J. Biol. Chem. 266:19867-19870) can be inserted immediately 5' of the start codon to enhance expression. Furthermore, for expression of NACHR subunits in
30 amphibian oocytes, it may be desirable to surround the subunit coding sequence with *Xenopus* β -globin gene 5' and 3' untranslated sequences for optimum protein production. For example, NACHR subunit coding sequences can be incorporated into vector pSP64T [see Krieg and Melton in
35 *Nucleic Acids Research* 12:7057-7070 (1984)], a modified form of pSP64 (available from Promega, Madison, WI). The

coding sequence is inserted between β -globin gene 5' and 3' untranslated sequences located downstream of the SP6 promoter. *In vitro* transcripts can then be generated from the resulting vector. The desirability of (or need
5 for) such modification may be empirically determined.

Those of skill in the art recognize that a variety of promoters, enhancers, signal sequences, and the like can be employed to promote the expression of the cloned sequences described herein. In addition, it is
10 readily recognized that the regulatory elements employed in a given construct need not be obtained from the same source. Indeed, the regulatory elements employed in a given construct can be obtained from different sources, such that various combinations of regulatory elements can
15 be combined in a particular construct for expression.

As used herein, expression refers to the process by which polynucleic acids are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleic acid is derived from
20 genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, SV40 polyadenylation and splice sites and sequences
25 necessary for maintaining the vector in bacteria, cytomegalovirus (CMV) promoter-based vectors such as pCDNA1 (Invitrogen, San Diego, CA), and MMTV promoter-based vectors such as pMAMneo (Clontech, Palo Alto, CA),
30 and modifications thereof.

Full-length DNAs encoding human neuronal NACHR subunits have been inserted into vector pCMV-T7, a pUC19-

based mammalian cell expression vector containing the CMV promoter/enhancer, SV40 splice/donor sites located immediately downstream of the promoter, a polylinker downstream of the splice/donor sites, followed by an SV40 polyadenylation signal. Placement of NACHR subunit DNA between the CMV promoter and SV40 polyadenylation signal provides for constitutive expression of the foreign DNA in a mammalian host cell transfected with the construct. For inducible expression of human NACHR subunit-encoding DNA in a mammalian cell, the DNA can be inserted into a plasmid such as pMSG. This plasmid contains the mouse mammary tumor virus (MMTV) promoter for steroid-inducible expression of operatively associated foreign DNA. If the host cell does not express endogenous glucocorticoid receptors required for uptake of glucocorticoids (i.e., inducers of the MMTV promoter) into the cell, it is necessary to additionally transfect the cell with DNA encoding the glucocorticoid receptor (ATCC accession no. 67200). Full-length human DNA clones encoding human α_3 , α_4 , α_7 , β_2 and β_4 have also been subcloned into pIBI24 (International Biotechnologies, Inc., New Haven, CT) or pCMV-T7-2 for synthesis of *in vitro* transcripts.

In accordance with another embodiment of the present invention, there are provided cells containing the above-described polynucleic acids (i.e., DNA or mRNA). Such host cells as bacterial, yeast, amphibian and mammalian cells can be used for replicating DNA and producing nACHR subunit(s). Methods for constructing expression vectors, preparing *in vitro* transcripts, transfecting DNA into mammalian cells, injecting oocytes, and performing electrophysiological and other analyses for assessing receptor expression and function as described herein are also described in PCT Application Nos. PCT/US91/02311 (now published as WO 91/15602), PCT/US91/05625 (now published as WO 92/02639) and PCT/US92/11090 (now published as WO 93/13423), and in

co-pending U.S. Application Serial Nos. 07/504,455, 07/563,751 and 07/812,254. The subject matter of each of these applications is hereby incorporated by reference herein in its entirety.

5 Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in
10 the art (see, e.g., Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press). Heterologous DNA may be introduced into host cells by any method known to those of skill in the art, such as transfection with a vector
15 encoding the heterologous DNA by CaPO_4 precipitation (see, e.g., Wigler et al. (1979) Proc. Natl. Acad. Sci. 76:1373-1376) or lipofectamine (GIBCO BRL #18324-012). Recombinant cells can then be cultured under conditions whereby the subunit(s) encoded by the DNA is (are)
20 expressed. Preferred cells include mammalian cells (e.g., HEK 293, CHO, GH3 and Ltk⁺ cells), yeast cells (e.g., methylotrophic yeast cells, such as *Pichia pastoris*), bacterial cells (e.g., *Escherichia coli*), and the like. Especially preferred cells are those which are
25 also capable of expressing endogenous or heterologous voltage-dependent calcium channels (see, for example, PCT Application No. US92/06903; now published as WO 93/04083).

 While the nucleic acids provided herein may be
30 expressed in any eukaryotic cell, including yeast cells (such as, for example, *P. pastoris* (see U.S. Patent Nos. 4,882,279, 4,837,148, 4,929,555 and 4,855,231), *Saccharomyces cerevisiae*, *Candida tropicalis*, *Hansenula polymorpha*, and the like), mammalian expression systems,
35 including commercially available systems and other such

systems known to those of skill in the art, for expression of nucleic acids encoding the human neuronal nicotinic AChR subunits provided herein are presently preferred. *Xenopus* oocytes are preferred for expression
5 of RNA transcripts of the DNA.

In preferred embodiments, DNA is ligated into a vector, and introduced into suitable host cells to produce transformed cell lines that express a specific human nNACHR receptor subunit, or specific combinations
10 of subunits. The resulting cell lines can then be produced in quantity for reproducible quantitative analysis of the effects of drugs on receptor function. In other embodiments, mRNA may be produced by *in vitro* transcription of DNA encoding each subunit. This mRNA,
15 either from a single subunit clone or from a combination of clones, can then be injected into *Xenopus* oocytes where the mRNA directs the synthesis of the human receptor subunits, which then form functional receptors. Alternatively, the subunit-encoding nucleic acids can be
20 directly injected into oocytes for expression of functional receptors. The transfected mammalian cells or injected oocytes may then be used in the methods of drug screening provided herein.

Cloned full-length DNA encoding any of the
25 subunits of human neuronal nicotinic AChR may be introduced into a plasmid vector for expression in a eukaryotic cell. Such DNA may be genomic DNA or cDNA. Host cells may be transfected with one or a combination of plasmids, each of which encodes at least one human
30 neuronal nicotinic AChR subunit.

Eukaryotic cells in which DNA or RNA may be introduced include any cells that are transfectable by such DNA or RNA or into which such DNA or RNA may be injected. Preferred cells are those that can be

transiently or stably transfected and also express the DNA and RNA. Presently most preferred cells are those that can form recombinant or heterologous human neuronal nicotinic AChRs comprising one or more subunits encoded
5 by the heterologous DNA. Such cells may be identified empirically or selected from among those known to be readily transfected or injected.

Exemplary cells for introducing DNA include cells of mammalian origin (e.g., COS cells, mouse L
10 cells, Chinese hamster ovary (CHO) cells, human embryonic kidney cells, African green monkey cells, GH3 cells and other such cells known to those of skill in the art), amphibian cells (e.g., *Xenopus laevis* oocytes), yeast cells (e.g., *Saccharomyces cerevisiae*, *Pichia pastoris*),
15 and the like. Exemplary cells for expressing injected RNA transcripts include *Xenopus laevis* oocytes. Cells that are preferred for transfection of DNA are known to those of skill in the art or may be empirically identified, and include HEK 293 (which are available from
20 ATCC under accession #CRL 1573); Ltk⁻ cells (which are available from ATCC under accession #CCL1.3); COS-7 cells (which are available from ATCC under accession #CRL 1651); GH3 rat pituitary tumor cells (ATCC Accession No. CCL 82.1) and DG44 cells (dhfr⁻ CHO cells; see, e.g.,
25 Urlaub et al. (1986) Cell. Molec. Genet. 12: 555). Presently preferred cells include DG44 cells, GH3 and HEK 293 cells, particularly HEK 293 cells that have been adapted for growth in suspension and that can be frozen in liquid nitrogen and then thawed and regrown. HEK 293
30 cells are described, for example, in U.S. Patent No. 5,024,939 to Gorman (see, also, Stillman et al. (1985) Mol. Cell. Biol. 5:2051-2060). Presently preferred cells also include those which are capable of expressing endogenous or heterologous voltage-dependent calcium
35 channels.

Nucleic acids may be stably incorporated into cells or may be transiently introduced using methods known in the art. Stably transfected mammalian cells may be prepared by transfecting cells with an expression
5 vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene. To produce such
10 cells, the cells should be transfected with a sufficient concentration of subunit-encoding nucleic acids to form human neuronal nicotinic AChRs that contain the human subunits encoded by heterologous DNA. The precise amounts and ratios of DNA encoding the subunits may be
15 empirically determined and optimized for a particular combination of subunits, cells and assay conditions. Recombinant cells that express neuronal nicotinic AChR containing subunits encoded only by the heterologous DNA or RNA are especially preferred.

20 Heterologous DNA may be maintained in the cell as an episomal element or may be integrated into chromosomal DNA of the cell. The resulting recombinant cells may then be cultured or subcultured (or passaged, in the case of mammalian cells) from such a culture or a
25 subculture thereof. Methods for transfection, injection and culturing recombinant cells are known to the skilled artisan. Similarly, the human neuronal nicotinic AChR subunits may be purified using protein purification methods known to those of skill in the art. For example,
30 antibodies or other ligands that specifically bind to one or more of the subunits may be used for affinity purification of the subunit or human neuronal nicotinic AChRs containing the subunits.

In accordance with yet another embodiment of
35 the present invention, there are provided antibodies

generated against the above-described subunit proteins. Such antibodies can be employed for studying receptor tissue localization, subunit composition, structure of functional domains, as well as in diagnostic
5 applications, therapeutic applications, and the like. Preferably, for therapeutic applications, the antibodies employed will be monoclonal antibodies.

The above-described antibodies can be prepared employing standard techniques, as are well known to those
10 of skill in the art, using the invention subunit proteins or portions thereof as antigens for antibody production. Both anti-peptide and anti-fusion protein antibodies can be used [see, for example, Bahouth et al. (1991) Trends Pharmacol Sci. vol. 12:338-343; Current Protocols in
15 Molecular Biology (Ausubel et al., eds.) John Wiley and Sons, New York (1989)]. Factors to consider in selecting portions of the NACHR subunits for use as immunogen (as either a synthetic peptide or a recombinantly produced bacterial fusion protein) include antigenicity,
20 accessibility (i.e., extracellular and cytoplasmic domains), uniqueness to the particular subunit, etc.

The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the distribution and
25 expression density of various subunits (e.g., in normal vs diseased brain tissue). Such antibodies could also be employed for diagnostic and therapeutic applications.

In accordance with still another embodiment of the present invention, there are provided methods for
30 modulating the ion channel activity of receptor(s) of the invention by contacting said receptor(s) with an effective amount of the above-described antibodies.

The antibodies of the invention can be administered to a subject employing standard methods, such as, for example, by intraperitoneal, intramuscular, intravenous, or subcutaneous injection, implant or
5 transdermal modes of administration, and the like. One of skill in the art can readily determine dose forms, treatment regimens, etc, depending on the mode of administration employed.

In accordance with one embodiment of the
10 present invention, methods for producing cells that express human neuronal nicotinic AChR subunits and functional receptors are also provided. In one such method, host cells are transfected with DNA encoding at least one alpha subunit of a neuronal nicotinic
15 acetylcholine receptor and at least one beta subunit of a neuronal nicotinic acetylcholine receptor. Using methods such as northern blot or slot blot analysis, transfected cells that contain alpha and/or beta subunit encoding DNA or RNA can be selected. Transfected cells are also
20 analyzed to identify those that express NACHR protein. Analysis can be carried out, for example, by measuring the ability of cells to bind acetylcholine, nicotine, or a nicotine agonist, compared to the nicotine binding ability of untransfected host cells or other suitable
25 control cells, by electrophysiologically monitoring the currents through the cell membrane in response to a nicotine agonist, and the like.

In particularly preferred aspects, eukaryotic cells which contain heterologous DNAs express such DNA
30 and form recombinant functional neuronal nicotinic AChR(s). In more preferred aspects, recombinant neuronal nicotinic AChR activity is readily detectable because it is a type that is absent from the untransfected host cell or is of a magnitude not exhibited in the untransfected
35 cell. Such cells that contain recombinant receptors

could be prepared, for example, by causing cells transformed with DNA encoding the human neuronal nicotinic AChR α_3 and β_4 subunits to express the corresponding proteins. The resulting synthetic or
5 recombinant receptors would contain only the α_3 and β_4 nNACHR subunits. Such receptors would be useful for a variety of applications, e.g., as part of an assay system free of the interferences frequently present in prior art assay systems employing non-human receptors or human
10 tissue preparations. Furthermore, testing of single receptor subunits with a variety of potential agonists or antagonists would provide additional information with respect to the function and activity of the individual subunits. Such information is expected to lead to the
15 identification of compounds which are capable of very specific interaction with one or more of the receptor subunits. Such specificity may prove of great value in medical application.

In another aspect, the invention comprises
20 functional peptide fragments, and functional combinations thereof, encoded by the DNAs of the invention. Such functional peptide fragments can be produced by those skilled in the art, without undue experimentation, by eliminating some or all of the amino acids in the
25 sequence not essential for the peptide to function as a NACHR. A determination of the amino acids that are essential for NACHR function is made, for example, by systematic digestion of the DNAs encoding the peptides and/or by the introduction of deletions into the DNAs.
30 The modified (e.g., deleted or digested) DNAs are expressed, for example, by transcribing the DNA and then introducing the resulting mRNA into *Xenopus* oocytes, where translation of the mRNAs will occur. Functional analysis of the proteins thus expressed in the oocytes is
35 accomplished by exposing the oocytes to ligands known to bind to and functionally activate NACHR, and then

monitoring the oocytes to see if endogenous channels are in turn activated. If currents are detected, the fragments are functional as NACHR.

Thus, DNA encoding one or more human neuronal
5 nicotinic AChR subunits may be introduced into suitable host cells (e.g., eukaryotic or prokaryotic cells) for expression of individual subunits and functional NACHRs. Preferably combinations of alpha and beta subunits may be introduced into cells: such combinations include
10 combinations of any one or more of α_1 , α_2 , α_3 , α_4 , α_5 and α_7 with β_2 or β_4 . Sequence information for α_1 is presented in Biochem. Soc. Trans. (1989) 17:219-220; sequence information for α_5 is presented in Proc. Natl. Acad. Sci.USA (1992) 89:1572-1576; and sequence information for
15 α_2 , α_3 , α_4 , α_7 , β_2 and β_4 is presented in the Sequence Listing provided herewith. Presently preferred combinations of subunits include any one or more of α_1 , α_2 , α_3 or α_4 with β_4 ; or α_2 , α_3 or α_4 in combination with either β_2 or β_4 . It is recognized that some of the
20 subunits may have ion transport function in the absence of additional subunits. For example, the α_7 subunit may function in the absence of any added beta subunit.

As used herein, " α_2 subunit DNA" refers to DNA that encodes a human neuronal nicotinic acetylcholine
25 receptor subunit of the same name, and to DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 1, or to the DNA of deposited clone having ATCC Accession No. 68277, or to DNA that encodes the amino acid sequence set forth in SEQ ID No. 2.
30 Typically, unless an α_2 subunit arises as a splice variant, an α_2 DNA shares substantial sequence homology (greater than about 90%) with the α_2 DNA described herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA
35 described herein, but such a splice variant would include

regions of nearly 100% homology to the above-described DNA.

As used herein, " α_3 subunit DNA" refers to DNA that encodes a neuronal subunit of the same name, and to
5 DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 3, or to the DNA of deposited clone having ATCC Accession No. 68278, or to DNA that encodes the amino acid sequence set forth in SEQ ID No. 4. Typically, unless an α_3 arises as a splice variant, an
10 α_3 DNA shares substantial sequence homology (greater than about 90%) with the α_3 DNA described herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly
15 100% homology to the above described DNA.

As used herein, " α_5 subunit DNA" refers to DNA that encodes a human neuronal nicotinic acetylcholine receptor subunit of the same name, as described, for example, by Chini et al. (1992) Proc. Natl. Acad. Sci.
20 USA 89:1572-1576.

As used herein, " β_2 subunit DNA" refers to DNA that encodes a neuronal subunit of the same name and, to DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 9, or to the DNA of deposited
25 clone HnAChR β_2 , having ATCC Accession No. 68279, or to DNA encoding the amino acid sequence set forth in SEQ ID No. 10. Typically, unless a β_2 subunit arises as a splice variant, a β_2 DNA shares substantial sequence homology (greater than about 90%) with the β_2 DNA described herein.
30 DNA or RNA encoding a splice variant may share overall less than 90% homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100% homology to the above-described DNA.

In certain embodiments, eukaryotic cells with heterologous human neuronal nicotinic AChRs are produced by introducing into the cell a first composition, which contains at least one RNA transcript that is translated
5 in the cell into a subunit of a human neuronal nicotinic AChR. In preferred embodiments, the subunits that are translated include an alpha subunit of a human neuronal nicotinic AChR. More preferably, the composition that is introduced contains an RNA transcript which encodes an
10 alpha subunit and also contains an RNA transcript which encodes a beta subunit of a human neuronal nicotinic AChR. RNA transcripts can be obtained from cells transfected with DNAs encoding human neuronal nicotinic acetylcholine receptor subunits or by *in vitro*
15 transcription of subunit-encoding DNAs. Methods for *in vitro* transcription of cloned DNA and injection of the resulting mRNA into eukaryotic cells are well known in the art. Amphibian oocytes are particularly preferred for expression of *in vitro* transcripts of the human
20 nAChR DNA clones provided herein. See, for example, Dascal (1989) CRC Crit. Rev. Biochem. 22:317-387, for a review of the use of *Xenopus* oocytes to study ion channels.

Thus, pairwise (or stepwise) introduction of
25 DNA or RNA encoding alpha and beta subunits into cells is possible. The resulting cells may be tested by the methods provided herein or known to those of skill in the art to detect functional AChR activity. Such testing will allow the identification of pairs of alpha and beta
30 subunits that produce functional AChRs, as well as individual subunits that produce functional AChRs.

As used herein, a recombinant or heterologous human neuronal nicotinic AChR refers to a receptor that contains one or more subunits encoded by heterologous DNA
35 that has been introduced into and expressed in cells

capable of expressing receptor protein. A recombinant human neuronal nicotinic AChR may also include subunits that are produced by DNA endogenous to the host cell. In certain embodiments, recombinant or heterologous human neuronal nicotinic AChR may contain only subunits that are encoded by heterologous DNA.

Recombinant receptors on recombinant eukaryotic cell surfaces may contain one or more subunits encoded by the DNA or mRNA encoding human neuronal nicotinic AChR subunits, or may contain a mixture of subunits encoded by the host cell and subunits encoded by heterologous DNA or mRNA. Recombinant receptors may be homogeneous or may be a mixture of subtypes. Mixtures of DNA or mRNA encoding receptors from various species, such as rats and humans, may also be introduced into the cells. Thus, a cell can be prepared that expresses recombinant receptors containing only α_3 and β_4 subunits, or any other combination of alpha and beta subunits provided herein. For example, α_4 and/or α_7 subunits of the present invention can be co-expressed with β_2 and/or β_4 receptor subunits; similarly, β_4 subunits according to the present invention can be co-expressed with α_2 , α_3 , α_4 , α_5 and/or α_7 receptor subunits. As noted previously, some of the nNACHR subunits may be capable of forming functional receptors in the absence of other subunits, thus co-expression is not always required to produce functional receptors.

As used herein, activity of a human neuronal nicotinic AChR refers to any activity characteristic of an NACHR. Such activity can typically be measured by one or more *in vitro* methods, and frequently corresponds to an *in vivo* activity of a human neuronal nicotinic AChR. Such activity may be measured by any method known to those of skill in the art, such as, for example,

measuring the amount of current which flows through the recombinant channel in response to a stimulus.

Methods to determine the presence and/or activity of human neuronal nicotinic AChRs include assays that measure nicotine binding, ^{86}Rb ion-flux, Ca^{2+} influx, the electrophysiological response of cells, the electrophysiological response of oocytes transfected with RNA from the cells, and the like. In particular, methods are provided herein for the measurement or detection of an AChR-mediated response upon contact of cells containing the DNA or mRNA with a test compound.

As used herein, a functional neuronal nicotinic AChR is a receptor that exhibits an activity of neuronal nicotinic AChRs as assessed by any *in vitro* or *in vivo* assay disclosed herein or known to those of skill in the art. Possession of any such activity that may be assessed by any method known to those of skill in the art and provided herein is sufficient to designate a receptor as functional. Methods for detecting NACHR protein and/or activity include, for example, assays that measure nicotine binding, ^{86}Rb ion-flux, Ca^{2+} influx, the electrophysiological response of cells containing heterologous DNA or mRNA encoding one or more receptor subunits, and the like. Since all combinations of alpha and beta subunits may not form functional receptors, numerous combinations of alpha and beta subunits should be tested in order to fully characterize a particular subunit and cells which produce same. Thus, as used herein, "functional" with respect to a recombinant or heterologous human neuronal nicotinic AChR means that the receptor channel is able to provide for and regulate entry of human neuronal nicotinic AChR-permeable ions, such as, for example, Na^+ , K^+ , Ca^{2+} or Ba^{2+} , in response to a stimulus and/or bind ligands with affinity for the receptor. Preferably such human neuronal nicotinic AChR

activity is distinguishable, such as by electrophysiological, pharmacological and other means known to those of skill in the art, from any endogenous nicotinic AChR activity that may be produced by the host
5 cell.

In accordance with a particular embodiment of the present invention, recombinant human neuronal nicotinic AChR-expressing mammalian cells or oocytes can be contacted with a test compound, and the modulating
10 effect(s) thereof can then be evaluated by comparing the AChR-mediated response in the presence and absence of test compound, or by comparing the AChR-mediated response of test cells, or control cells (i.e., cells that do not express nNACHRs), to the presence of the compound.

15 As used herein, a compound or signal that "modulates the activity of a neuronal nicotinic AChR" refers to a compound or signal that alters the activity of NACHR so that activity of the NACHR is different in the presence of the compound or signal than in the
20 absence of the compound or signal. In particular, such compounds or signals include agonists and antagonists. The term agonist refers to a substance or signal, such as ACh, that activates receptor function; and the term antagonist refers to a substance that interferes with
25 receptor function. Typically, the effect of an antagonist is observed as a blocking of activation by an agonist. Antagonists include competitive and non-competitive antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site
30 specific for the agonist (e.g., ligand or neurotransmitter) for the same or closely situated site. A non-competitive antagonist or blocker inactivates the functioning of the receptor by interacting with a site other than the site that interacts with the agonist.

As understood by those of skill in the art, assay methods for identifying compounds that modulate human neuronal nicotinic AChR activity (e.g., agonists and antagonists) generally require comparison to a control. One type of a "control" cell or "control" culture is a cell or culture that is treated substantially the same as the cell or culture exposed to the test compound, except the control culture is not exposed to test compound. For example, in methods that use voltage clamp electrophysiological procedures, the same cell can be tested in the presence and absence of test compound, by merely changing the external solution bathing the cell. Another type of "control" cell or "control" culture may be a cell or a culture of cells which are identical to the transfected cells, except the cells employed for the control culture do not express functional human neuronal nicotinic AChRs. In this situation, the response of test cell to test compound is compared to the response (or lack of response) of receptor-negative (control) cell to test compound, when cells or cultures of each type of cell are exposed to substantially the same reaction conditions in the presence of compound being assayed.

The functional recombinant human neuronal nicotinic AChR includes at least an alpha subunit, or an alpha subunit and a beta subunit of a human neuronal nicotinic AChR. Eukaryotic cells expressing these subunits have been prepared by injection of RNA transcripts and by transfection of DNA. Such cells have exhibited nicotinic AChR activity attributable to human neuronal nicotinic AChRs that contain one or more of the heterologous human neuronal nicotinic AChR subunits. For example, *Xenopus laevis* oocytes that had been injected with *in vitro* transcripts of the DNA encoding human neuronal nicotinic AChR α_3 and β_4 subunits exhibited AChR agonist induced currents; whereas cells that had been

injected with transcripts of either the α_3 or β_4 subunit alone did not. In addition, HEK 293 cells that had been co-transfected with DNA encoding human neuronal NACHR α_3 and β_4 subunits exhibited AChR agonist-induced increases in intracellular calcium concentration, whereas control HEK 293 cells (i.e., cells that had not been transfected with α_3 - and β_4 -encoding DNA) did not exhibit any AChR agonist-induced increases in intracellular calcium concentration.

With respect to measurement of the activity of functional heterologous human neuronal nicotinic AChRs, endogenous AChR activity and, if desired, activity of AChRs that contain a mixture of endogenous host cell subunits and heterologous subunits, should, if possible, be inhibited to a significant extent by chemical, pharmacological and electrophysiological means.

Deposits

The deposited clones have been deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, U.S.A. 20852, under the terms of the Budapest Treaty on the International Recognition of Deposits of Microorganisms for Purposes of Patent Procedure and the Regulations promulgated under this Treaty. Samples of the deposited material are and will be available to industrial property offices and other persons legally entitled to receive them under the terms of the Treaty and Regulations and otherwise in compliance with the patent laws and regulations of the United States of America and all other nations or international organizations in which this application, or an application claiming priority of this application, is filed or in which any patent granted on any such application is granted. In particular, upon issuance of a U.S. patent based on this or any application claiming

priority to or incorporating this application by reference thereto, all restrictions upon availability of the deposited material will be irrevocably removed.

The invention will now be described in greater detail with reference to the following non-limiting examples.

Example 1

Isolation of DNA Encoding Human nNACHR Subunits

A. DNA Encoding a Human nNACHR β_4 Subunit

Random primers were used in synthesizing cDNA from RNA isolated from the IMR32 human neuroblastoma cell line (the cells had been grown in 1mM dibutyryl cAMP for 10 days prior to constructing the library). The library constructed from the cDNAs was screened with a fragment of a rat nicotinic AChR β_4 subunit cDNA. Hybridization was performed at 42°C in 5X SSPE, 5X Denhardt's solution, 50% formamide, 200 µg/ml herring sperm DNA and 0.2% SDS. Washes were performed in 0.1X SSPE, 0.2% SDS at 65°C. Five clones were identified that hybridized to the probe.

The five clones were plaque-purified and characterized by restriction enzyme mapping and DNA sequence analysis. The insert DNA of one of the five clones contained the complete coding sequence of a β_4 subunit of a human nicotinic AChR (see nucleotides 87-1583 of SEQ ID No. 11). The amino acid sequence deduced from the nucleotide sequence of the full-length clone has ~82% identity with the amino acid sequence deduced from the rat nicotinic AChR β_4 subunit DNA. Several regions of the deduced rat and human β_4 amino acid sequences are notably dissimilar: amino acids 1-23 (the human sequence has only ~36% identity with respect to the rat sequence), 352-416 (the human sequence has only ~48% identity with

respect to the rat sequence), and 417-492 (the human sequence has only ~78% identity with respect to the rat sequence). Furthermore, amino acids 376-379 in the rat β_4 subunit are not contained in the human β_4 subunit.

5 B. DNA Encoding a Human nNACHR α_7 Subunit

An amplified IMR32 cell cDNA library (1×10^6 recombinants; cells treated for 10 days with 1mM dibutyryl cAMP prior to library construction) was screened with a fragment of a rat nicotinic AChR α_7 subunit cDNA. The hybridization conditions were identical to those described above for screening an IMR32 cell cDNA library with the rat β_4 subunit DNA. Washes were performed in 0.2X SSPE, 0.2% SDS at 65°C. Seven positive clones were identified by hybridization to the labeled rat DNA probe. Six of the clones were plaque-purified and characterized by restriction enzyme mapping and DNA sequence analysis. One of the clones contains the complete coding sequence of a human AChR receptor α_7 subunit gene (see nucleotides 73-1581 of SEQ ID No. 7).

20 C. DNA Encoding a Human nNACHR α_4 Subunit

Random primers were used in synthesizing cDNA from RNA isolated from human hippocampus tissue. cDNAs larger than 2.0 kb were inserted into the λ gt10 phage vector to create a cDNA library. Approximately 1×10^6 recombinants were screened with a fragment of a DNA encoding a rat nicotinic AChR α_4 subunit using the same hybridization and washing conditions as described above for screening an IMR32 cell cDNA library for α_7 subunit cDNAs. Three clones hybridized strongly to the probe. Two of these three clones, designated KE α 4.1 and KE α 4.2, have been deposited with the American Type Culture Collection (ATCC, Rockville, MD) and assigned accession nos. 69152 and 69239, respectively.

Characterization of the plaque-purified clones revealed that one of the clones, KE α 4.2, contains the complete coding sequence of a human nicotinic AChR α 4 subunit gene (coding sequence of this human α 4 subunit cDNA is provided as nucleotides 173-2056 in SEQ ID No. 5). Comparison of the 5' ends of the coding sequences of the human and rat α 4 subunit cDNAs reveals, among other differences, that the rat sequence contains an 18-nucleotide segment that is not present in the human sequence.

D. DNA Encoding Human nNACHR α_2 , α_3 , & β_2 Subunits

Plasmids containing DNA that encodes and/or that can be used to isolate nucleic acids that encode human neuronal nicotinic acetylcholine receptor α_2 , α_3 and β_2 subunits have been deposited with the American Type Culture Collection (ATCC). The clone names and deposit accession numbers are:

| | <u>Subunit</u> | <u>Clone Name</u> | <u>ATCC Accession No.</u> |
|----|----------------|-------------------|---------------------------|
| | α_2 | HnAChR α 2 | 68277 |
| 20 | α_3 | HnACHR α 3 | 68278 |
| | β_2 | HnAChR β 2 | 68279 |

In addition, DNA sequences that encode full-length α_2 , α_3 and β_2 subunits are set forth in SEQ ID Nos. 1, 3 and 9, respectively.

Example 2Preparation of Constructs for the Expression of
Recombinant Human Neuronal Nicotinic AChR Subunits

Isolated cDNAs encoding human neuronal
5 nicotinic AChR subunits were incorporated into vectors
for use in expressing the subunits in mammalian host
cells and for use in generating *in vitro* transcripts to
be expressed in *Xenopus* oocytes. Several different
vectors were utilized in preparing the constructs as
10 follows.

A. Construct for Expression of a Human nNACHR α_3
Subunit

DNA encoding a human neuronal nicotinic AChR α_3
subunit was subcloned into the pCMV-T7-2 general
15 expression vector to create pCMV-KE α_3 . Plasmid pCMV-T7-2
(see Figure 1) is a pUC19-based vector that contains a
CMV promoter/enhancer, SV40 splice donor/splice acceptor
sites located immediately downstream of the promoter, a
T7 bacteriophage RNA polymerase promoter positioned
20 downstream of the SV40 splice sites, an SV40
polyadenylation signal downstream of the T7 promoter, and
a polylinker between the T7 promoter and the
polyadenylation signal. This vector thus contains all
the regulatory elements required for expression of
25 heterologous DNA in a mammalian host cell, wherein the
heterologous DNA has been incorporated into the vector at
the polylinker. In addition, because the T7 promoter is
located just upstream of the polylinker, this plasmid can
be used for synthesis of *in vitro* transcripts from
30 heterologous DNA that has been subcloned into the vector
at the polylinker. Figure 1 also shows a restriction map
of pCMV-T7-3. This plasmid is identical to pCMV-T7-2
except that the restriction sites in the polylinker are

in the opposite order as compared to the order in which they occur in pCMV-T7-2.

A 1.7 kb *Sfi*I (blunt-ended)/*Eco*RI DNA fragment containing nucleotides 27-1757 of SEQ ID No. 3 (i.e., the entire α_3 subunit coding sequence plus 12 nucleotides of 5' untranslated sequence and 204 nucleotides of 3' untranslated sequence) was ligated to *Eco*RV/*Eco*RI-digested pCMV-T7-2 to generate pCMV-KE α_3 . Plasmid pCMV-KE α_3 was used for expression of the α_3 subunit in mammalian cells and for generating *in vitro* transcripts from the α_3 subunit DNA.

B. Constructs for Expression of a Human nNACHR β_4 Subunit

A 1.9 kb *Eco*RI DNA fragment containing nucleotides 1-1915 of SEQ ID No. 11 (i.e., the entire β_4 subunit coding sequence plus 86 nucleotides of 5' untranslated sequence and 332 nucleotides of 3' untranslated sequence) was ligated to *Eco*RI-digested pGEM7Zf(+) (Promega Catalog #P2251; Madison, WI). The resulting construct, KE β_4 .6/pGEM, contains the T7 bacteriophage RNA polymerase promoter in operative association with two tandem β_4 subunit DNA inserts (in the same orientation) and was used in generating *in vitro* transcripts from the DNA.

The same 1.9 kb *Eco*RI DNA fragment containing nucleotides 1-1915 of SEQ ID No. 11 was ligated as a single insert to *Eco*RI-digested pCMV-T7-3 to generate pCMV-KE β_4 . Plasmid pCMV-KE β_4 was used for expression of the β_4 subunit in mammalian cells and for generating *in vitro* transcripts of the β_4 subunit DNA.

C. Constructs for Expression of a Human nNACHR α_7 Subunit

Two pCMV-T7-based constructs were prepared for use in recombinant expression of a human neuronal
5 nicotinic AChR α_7 subunit. The first construct, pCMV-KE α_7 .3, was prepared by ligating a 1.9 kb XhoI DNA fragment containing nucleotides 1-1876 of SEQ ID No. 7 (i.e., the entire α_7 subunit coding sequence plus 72
10 nucleotides of 5' untranslated sequence and 295 nucleotides of 3' untranslated sequence) to SalI-digested pCMV-T7-3. The second construct, pCMV-KE α_7 , was prepared by replacing the 5' untranslated sequence of the 1.9 kb XhoI α_7 subunit DNA fragment described above with a
15 consensus ribosome binding site (5'-GCCACC-3'; see Kozak (1987) Nucl. Acids Res. 15:8125-8148). The resulting modified fragment was ligated as a 1.8 kb BglII/XhoI fragment with BglII/SalI-digested pCMV-T7-2 to generate pCMV-KE α_7 . Thus, in pCMV-KE α_7 , the translation
20 initiation codon of the coding sequence of the α_7 subunit cDNA is preceded immediately by a consensus ribosome binding site.

D. Constructs for Expression of a Human nNACHR β_2 Subunit

DNA fragments encoding portions of a human
25 neuronal nicotinic AChR β_2 subunit were ligated together to generate a full-length β_2 subunit coding sequence contained in plasmid pIBI24 (International Biotechnologies, Inc. (IBI), New Haven, CT). The
30 resulting construct, H β_2 .1F, contains nucleotides 1-2448 of SEQ ID No. 9 (i.e., the entire β_2 subunit coding sequence, plus 264 nucleotides of 5' untranslated sequence and 675 nucleotides of 3' untranslated sequence) in operative association with the T7 promoter.

Because the 5' untranslated sequence of the β_2 subunit DNA contains a potential alternative translation initiation codon (ATG) beginning 11 nucleotides upstream (nucleotides 254-256 in SEQ ID No. 9) of the correct translation initiation codon (nucleotides 265-267 in SEQ ID No. 9), and because the use of the upstream ATG sequence to initiate translation of the β_2 DNA might result in the generation of an inoperative peptide (because the upstream ATG is not in the correct reading frame), an additional β_2 -encoding construct was prepared as follows. A 2.2 kb *KspI* (blunt ended)/*EcoRI* DNA fragment containing nucleotides 260-2448 of SEQ ID No. 9 was ligated to *NotI* (blunt ended)/*EcoRI*-digested pCMV-T7-3 in operative association with the T7 promoter of the plasmid to create pCMV-KE β_2 . The β_2 subunit DNA contained in pCMV-KE β_2 retains only 5 nucleotides of 5' untranslated sequence upstream of the correct translation initiation codon.

DNA encoding a human NACHR β_2 subunit was also incorporated into expression vector pSP64T. Vector pSP64T [see Krieg and Melton in *Nucleic Acids Research* 12:7057-7070 (1984)] is a modified form of vector pSP64 (Promega). The human NACHR β_2 subunit coding sequence (preceded by the consensus ribosome binding site), plus 405 nucleotides of 3' untranslated region, were incorporated into pSP64T at a unique restriction enzyme cloning site that is flanked by 5' and 3' untranslated sequences from the *Xenopus* β -globin gene. These sequences are located downstream of the SP6 promoter contained in pSP64T. The resulting vector, pSP64T-KE β_2 RBS1, contains the human β_2 subunit coding sequence in operable association with SP6 transcription regulatory regions for the production of *in vitro* transcripts of the heterologous DNA using the MEGAscript SP6 kit (Ambion, Catalog No. 1330).

E. Constructs for Expression of a Human nNACHR α_4 Subunit

A portion of the insert of clone KE α 4.2 (see Example 1C), containing a human nNACHR α_4 subunit coding sequence, was incorporated into a modified vector pIBI24 as follows. Vector pIBI24 was modified by inserting a consensus ribosome binding site into the polylinker just upstream of an *NotI* site. The vector was digested with *HindIII* and *NcoI*. An *NcoI-HindIII* fragment containing a human nNACHR α_4 subunit coding sequence was obtained by digestion of a human nNACHR α_4 subunit cDNA-containing plasmid with *HindIII* (which cuts in a polylinker immediately 3' to the 3'untranslated sequence of KE α 4.2 (see SEQ ID NO:5), followed by partial digestion with *NcoI* (to maintain an internal *NcoI* site, i.e., position 1956, SEQ ID NO:5) to cut at the junction of the translation initiation codon and 5' untranslated sequence of the α_4 subunit-encoding cDNA. The resulting 3.25 kb fragment was ligated with the *HindIII-NcoI* fragment of the modified pIBI24 vector to create pIBI-KE α 4RBSf. Thus, pIBI-KE α 4RBSf contains a consensus ribosome binding site followed immediately by the human nNACHR α_4 subunit coding sequence (nucleotides 173-2056 of SEQ ID NO:5) and ~1400 nucleotides of 3' untranslated sequence (including nucleotides 2057 - 2363 of SEQ ID NO:5). Because this construct contains a T7 promoter upstream of the α_4 subunit coding sequence, it can be used in generating *in vitro* transcripts from α_4 DNA.

Example 3Expression of Recombinant Human Nicotinic AChR in Oocytes

Xenopus oocytes were injected with *in vitro* transcripts prepared from constructs containing DNA
5 encoding α_3 , α_7 , β_2 and β_4 subunits. Electrophysiological measurements of the oocyte transmembrane currents were made using the two-electrode voltage clamp technique (see, e.g., Stuhmer (1992) *Meth. Enzymol.* 207:319-339).

1. Preparation of *in vitro* transcripts

10 Recombinant capped transcripts of pCMV-KE α 3, pCMV-KE β 2, KE β 4.6/pGEM and pCMV-KE β 4 were synthesized from linearized plasmids using the mCAP RNA Capping Kit (Cat. #200350 from Stratagene, Inc., La Jolla, CA). Recombinant capped transcripts of pCMV-KE α 7, pCMV-KE α 7.3,
15 pIBI-KE α 4RBSf and H β 2.1F were synthesized from linearized plasmids using the MEGAscript T7 *in vitro* transcription kit according to the capped transcript protocol provided by the manufacturer (Catalog #1334 from AMBION, Inc., Austin, TX). The mass of each synthesized transcript was
20 determined by UV absorbance and the integrity of each transcript was determined by electrophoresis through an agarose gel.

2. Electrophysiology

Xenopus oocytes were injected with either 12.5,
25 50 or 125 ng of human nicotinic AChR subunit transcript per oocyte. The preparation and injection of oocytes were carried out as described by Dascal (1987) in *Crit. Rev. Biochem.* 22:317-387. Two-to-six days following mRNA injection, the oocytes were examined using the two-
30 electrode voltage clamp technique. The cells were bathed in Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl₂, 10 mM HEPES, pH 7.3) containing 1 μ M atropine with

or without 100 μM d-tubocurarine. Cells were voltage-clamped at -60 to -80 mV. Data were acquired with Axotape software at 2-5 Hz. The agonists acetylcholine (ACh), nicotine, and cytisine were added at

5 concentrations ranging from 0.1 μM to 100 μM . The results of electrophysiological analyses of the oocytes are summarized in Table 1.

Table 1

| | Template, ng RNA injected | Number of oocytes responding | Agonists | Current Amplitude |
|----|--|------------------------------|--|-------------------|
| 5 | pcMV-KE α 3, 12.5 ng | 0 of 8 | ACh, Nicotine | |
| | KE β 4.6/pGEM, 12.5 ng | 0 of 9 | ACh, Nicotine | |
| | pcMV-KE α 3, 12.5 ng + KE β 4.6/pGEM, 12.5 ng | 4 of 5 | ACh, Nicotine | 20-550 nA |
| 10 | pcMV-KE α 3, 12.5 ng + KE β 4.6/pGEM, 12.5 ng | 3 of 4 | ACh, Cytisine, Nicotine | 20-300 nA |
| 15 | pcMV-KE α 3, 125 ng + and pcMV-KE β 4, 125 ng | 5 of 5 | ACh, Nicotine, Cytisine | 200-500 nA |
| | pcMV-KE α 3, 125 ng + pcMV-KE β 4, 125 ng | 6 of 6 | ACh, Nicotine, Cytisine | 100-400 nA |
| | pcMV-KE α 7.3, 125 ng | 3 of 15 | ACh | ~20 nA |
| 20 | pcMV-KE α 7, 125 ng | 11 of 11 | ACh | 20-250 nA |
| | pcMV-KE α 3, 12.5 ng + pcMV-KE β 2, 12.5 ng | 2 of 9 | ACh, Nicotine | <10 nA |
| 25 | pcMV-KE α 3, 125 ng + pcMV-KE β 2, 125 ng | 0 of 9 | ACh, Nicotine | |
| | pcMV-KE α 3, 125 ng + H β 2.1F, 125 ng | 13 of 16 | ACh (100 μ M) ACh (300 μ M) | ~20 nA ~80 nA |
| 30 | pIBI-KE α 4RBSf, 125 ng + pcMV-KE β 4, 125 ng | 3 of 3 | ACh (30 μ M) | ~40 nA |

a. Oocytes Injected with α_3 , α_4 and/or β_4 Transcripts

35 Oocytes that had been injected with 12.5 ng of the α_3 transcript or 12.5 ng of the β_4 transcript did not

respond to application of up to 100 μM ACh, nicotine or cytisine. Thus, it appears that these subunits do not form functional homomeric nicotinic AChR channels. By contrast, oocytes injected with 12.5 or 125 ng of the α_3 transcript and 12.5 ng or 125 ng of the β_4 transcript exhibited detectable inward currents in response to ACh, nicotine, and cytisine at the tested concentrations (0.1 μM to 10 μM). Some differences in the kinetics of the responses to cytisine compared to nicotine and ACh were observed. The relative potency of the agonists appeared to be cytisine > ACh > nicotine, which differs from the results of similar studies of oocytes injected with transcripts of the rat nicotinic AChR α_3 and β_4 subunits (see, for example, Luetje et al. (1991) *J. Neurosci.* 11:837-845).

The responses to ACh and nicotine were reproducibly blocked by d-tubocurarine. For example, complete blockage of the response to ACh was observed in the presence of 100 μM d-tubocurarine. The inhibition appeared to be reversible. The responses to ACh, nicotine and cytisine were also at least partially blocked by 100 nM mecamylamine.

The current response of α_3 - β_4 -injected oocytes to 10 μM ACh was also examined in terms of membrane voltage. In these experiments, voltage steps were applied to the cells in the presence of ACh. The graph of current vs. voltage appeared typical of responses observed for Na^+ , K^+ -permeable channels. For example, the zero current level (reversal potential) is less than -40 mV. The contribution of Ca^{++} flux to the total current can be ascertained by varying the calcium concentration in the external medium and taking multiple current measurements at different holding potentials around the reversal potential. Such studies indicate that the channel carrying the current generated in

response to ACh treatment of α_3 - β_4 -injected oocytes is permeable to Na^+ , K^+ and Ca^{++} .

As shown in Table 1, oocytes injected with 125 ng of the α_4 transcript and 125 ng of the β_4 transcript also exhibited detectable inward currents in response to acetylcholine.

b. Oocytes injected with α_7 subunit transcripts

As described in Example 2, two constructs were prepared for use in expressing the human neuronal nicotinic AChR α_7 subunit. Plasmid pCMV-KE α 7.3 contains the α_7 subunit coding sequence with 72 nucleotides of 5' untranslated sequence upstream of the translation initiation codon. Plasmid pCMV-KE α 7 contains the α_7 subunit coding sequence devoid of any 5' untranslated sequence and further contains a consensus ribosome binding site immediately upstream of the coding sequence.

Oocytes injected with 125 ng of α_7 transcript synthesized from pCMV-KE α 7 displayed inward currents in response to 10 or 100 μM ACh. This response was blocked by 100 μM d-tubocurarine.

Oocytes injected with 125 ng of α_7 transcript synthesized from pCMV-KE α 7.3 exhibited ACh-induced currents that were substantially weaker than those of oocytes injected with α_7 transcript synthesized from pCMV-KE α 7. These results indicate that human neuronal nicotinic AChR α_7 subunit transcripts generated from α_7 subunit DNA containing a ribosome binding site in place of 5' untranslated sequence may be preferable for expression of the α_7 receptor in oocytes.

c. Oocytes injected with α_3 and β_2
subunit transcripts

As described in Example 2, two constructs were prepared for use in expressing the human neuronal
5 nicotinic AChR β_2 subunit. Plasmid H β_2 .1F contains the β_2 subunit coding sequence with 266 nucleotides of 5' untranslated sequence upstream of the translation initiation codon. Plasmid pCMV-KE β_2 contains the β_2 subunit coding sequence and only 5 nucleotides of 5'
10 untranslated sequence upstream of the translation initiation codon.

Oocytes injected with transcripts of pCMV-KE α_3 and pCMV-KE β_2 displayed substantially no current in response to nicotinic AChR agonists. In contrast,
15 oocytes injected with transcripts of pCMV-KE α_3 and H β_2 .1F displayed ~20 nA inward currents in response to 100 μ M ACh and ~80 nA inward currents in response to 300 μ M ACh. The current response was blocked by 100 μ M d-tubocurarine.

20

Example 4

Recombinant Expression of Human nNACHR
Subunits in Mammalian Cells

Human embryonic kidney (HEK) 293 cells were transiently and stably transfected with DNA encoding
25 human neuronal nicotinic AChR α_3 and β_4 , or α_7 subunits. Transient transfectants were analyzed for expression of nicotinic AChR using various assays, e.g., electrophysiological methods, Ca^{2+} -sensitive fluorescent indicator-based assays and [^{125}I]- α -bungarotoxin-binding
30 assays.

1. Transient Transfection of HEK Cells

Two transient transfections were performed. In one transfection, HEK cells were transiently co-transfected with DNA encoding α_3 (plasmid pCMV-KE α_3) and β_4 (plasmid pCMV-KE β_4) subunits. In the other transfection, HEK cells were transiently transfected with DNA encoding the α_7 subunit (plasmid pCMV-KE α_7). In both transfections, $\sim 2 \times 10^6$ HEK cells were transiently transfected with 18 μg of the indicated plasmid(s) according to standard CaPO_4 transfection procedures [Wigler et al. (1979) *Proc. Natl. Acad. Sci. USA* 76:1373-1376]. In addition, 2 μg of plasmid pCMV βgal (Clontech Laboratories, Palo Alto, CA), which contains the *Escherichia coli* β -galactosidase gene fused to the CMV promoter, were co-transfected as a reporter gene for monitoring the efficiency of transfection. The transfectants were analyzed for β -galactosidase expression by measurement of β -galactosidase activity [Miller (1972) *Experiments in Molecular Genetics*, pp.352-355, Cold Spring Harbor Press]. Transfectants can also be analyzed for β -galactosidase expression by direct staining of the product of a reaction involving β -galactosidase and the X-gal substrate [Jones (1986) *EMBO* 5:3133-3142].

The efficiency of transfection of HEK cells with pCMV-KE α_3 /pCMV-KE β_4 was typical of standard efficiencies, whereas the efficiency of transfection of HEK cells with pCMV-KE α_7 was below standard levels.

2. Stable Transfection of HEK Cells

HEK cells were transfected using the calcium phosphate transfection procedure [*Current Protocols in Molecular Biology*, Vol. 1, Wiley Inter-Science, Supplement 14, Unit 9.1.1-9.1.9 (1990)]. Ten-cm plates,

each containing one-to-two million HEK cells were transfected with 1 ml of DNA/calcium phosphate precipitate containing 9.5 μ g pCMV-KE α 3, 9.5 μ g pCMV-KE β 4 and 1 μ g pSV2neo (as a selectable marker). After 14 days of growth in media containing 1 μ g/ml G418, colonies had formed and were individually isolated by using cloning cylinders. The isolates were subjected to limiting dilution and screened to identify those that expressed the highest level of nicotinic AChR, as described below.

3. Analysis of Transfectants

a. Fluorescent indicator-based assays

Activation of the ligand-gated nicotinic AChR by agonists leads to an influx of cations, including Ca⁺⁺, through the receptor channel. Ca⁺⁺ entry into the cell through the channel can induce release of calcium contained in intracellular stores. Monovalent cation entry into the cell through the channel can also result in an increase in cytoplasmic Ca⁺⁺ levels through depolarization of the membrane and subsequent activation of voltage-dependent calcium channels. Therefore, methods of detecting transient increases in intracellular calcium concentration can be applied to the analysis of functional nicotinic AChR expression. One method for measuring intracellular calcium levels relies on calcium-sensitive fluorescent indicators.

Calcium-sensitive indicators, such as fluo-3 (Catalog No. F-1241, Molecular Probes, Inc., Eugene, OR), are available as acetoxymethyl esters which are membrane permeable. When the acetoxymethyl ester form of the indicator enters a cell, the ester group is removed by cytosolic esterases, thereby trapping the free indicator in the cytosol. Interaction of the free indicator with calcium results in increased fluorescence of the

indicator; therefore, an increase in the intracellular Ca^{2+} concentration of cells containing the indicator can be expressed directly as an increase in fluorescence. An automated fluorescence detection system for assaying
5 nicotinic AChR has been described in commonly assigned pending US Patent Application No. 07/812,254 and corresponding PCT Patent Application No. US92/11090.

HEK cells that were transiently or stably co-transfected with DNA encoding $\alpha 3$ and $\beta 4$ subunits were
10 analyzed for expression of functional recombinant nicotinic AChR using the automated fluorescent indicator-based assay. The assay procedure was as follows.

Untransfected HEK cells (or HEK cells transfected with pCMV-T7-2) and HEK cells that had been
15 co-transfected with pCMV-KE $\alpha 3$ and pCMV-KE $\beta 4$ were plated in the wells of a 96-well microtiter dish and loaded with fluo-3 by incubation for 2 hours at 20°C in a medium containing 20 μM fluo-3, 0.2% Pluronic F-127 in HBS (125 mM NaCl, 5 mM KCl, 1.8 mM CaCl_2 , 0.62 mM MgSO_4 , 6 mM
20 glucose, 20 mM HEPES, pH 7.4). The cells were then washed with assay buffer (i.e., HBS). The antagonist d-tubocurarine was added to some of the wells at a final concentration of 10 μM . The microtiter dish was then placed into a fluorescence plate reader and the basal
25 fluorescence of each well was measured and recorded before addition of 200 μM nicotine to the wells. The fluorescence of the wells was monitored repeatedly during a period of approximately 60 seconds following addition of nicotine.

30 The fluorescence of the untransfected HEK cells (or HEK cells transfected with pCMV-T7-2) did not change after addition of nicotine. In contrast, the fluorescence of the co-transfected cells, in the absence of d-tubocurarine, increased dramatically after addition

of nicotine to the wells. This nicotine-stimulated increase in fluorescence was not observed in co-transfected cells that had been exposed to the antagonist d-tubocurarine. These results demonstrate
5 that the co-transfected cells express functional recombinant AChR that are activated by nicotine and blocked by d-tubocurarine.

b. α -Bungarotoxin binding assays

HEK293 cells transiently transfected with
10 pCMV-KE α 7 were analyzed for [125 I]- α -bungarotoxin (BgTx) binding. Both whole transfected cells and membranes prepared from transfected cells were examined in these assays. Rat brain membranes were included in the assays as a positive control.

15 Rat brain membranes were prepared according to the method of Hampson et al. (1987) J. Neurochem 49:1209. Membranes were prepared from the HEK cells transfected with pCMV-KE α 7 and HEK cells transiently transfected with plasmid pUC19 only (negative control) according to the
20 method of Perez-Reyes et al. (1989) Nature 340:233. Whole transfected and negative control cells were obtained by spraying the tissue culture plates with phosphate-buffered saline containing 0.1% (w/v) BSA. The cells were then centrifuged at low speed, washed once,
25 resuspended in assay buffer (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgSO₄, 20 mM HEPES, 0.1% (w/v) BSA, 0.05% (w/v) bacitracin and 0.5 mM PMSF, pH 7.5) and counted.

Specific binding of [125 I]- α -BgTx to rat brain
30 membranes was determined essentially as described by Marks et al. (1982) Molec. Pharmacol. 22:554-564, with several modifications. The membranes were washed twice in assay buffer. The assay was carried out in 12 x 75 mm

polypropylene test tubes in a total volume of 0.5 ml assay buffer. The membranes were incubated with 10 nM [125 I]- α -BgTx (New England Nuclear, Boston, MA) for one hour at 37°C. The assay mixtures were then centrifuged at 2300 x g for 10 minutes at 4°C. The supernatant was decanted and the pellets were washed twice with 2 ml aliquots of ice-cold assay buffer. The supernatants were decanted again and the radioactivity of the pellets was measured in a γ -counter. Non-specific binding was determined in the presence of 1 μ M unlabeled α -BgTx. Specific binding was determined by subtracting nonspecific binding from total binding. Specific binding of [125 I]- α -BgTx to membranes prepared from transfected and negative control cells was determined as described for determining specific binding to rat brain membranes except that the assay buffer did not contain BSA, bacitracin and PMSF. Specific binding of [125 I]- α -BgTx to transfected and negative control whole cells was determined basically as described for determining specific binding to rat brain membranes.

[125 I]- α -BgTx binding was evaluated as a function of membrane concentration and as a function of incubation time. [125 I]- α -BgTx binding to rat brain membranes increased in a linear fashion with increasing amounts of membrane (ranging between 25-500 μ g). The overall signal-to-noise ratio of binding (i.e., ratio of total binding to non-specific binding) was 3:1. Although some binding of [125 I]- α -BgTx to transfected cell membranes was detected, it was mostly non-specific binding and did not increase with increasing amounts of membrane. [125 I]- α -BgTx binding to the transfectants and negative control cells appeared to be similar.

To monitor [125 I]- α -BgTx binding to rat brain membranes and whole transfected and negative control cells, 300 μ g of membrane or 500,000 cells were incubated

with 1 nM or 10 nM [125 I]- α -BgTx, respectively, at 37°C for various times ranging from 0-350 min. Aliquots of assay mixture were transferred to 1.5 ml microfuge tubes at various times and centrifuged. The pellets were
5 washed twice with assay buffer. [125 I]- α -BgTx binding to rat brain membranes increased with time and was maximal after three hours. The binding profiles of the transfected and negative control cells were the same and differed from that of rat brain membranes.

10

Example 5

Characterization of Cell Lines Expressing nNACHRs

Recombinant cell lines generated by transfection with DNA encoding human neuronal nicotinic AChRs, such as those described in Example 3, can be
15 further characterized using one or more of the following methods.

A. Northern or slot blot analysis for expression of α - and/or β -subunit encoding messages

20 Total RNA is isolated from $\sim 1 \times 10^7$ cells and 10-15 μ g of RNA from each cell type is used for northern or slot blot hybridization analysis. The inserts from human neuronal NACHR-encoding plasmids can be nick-translated and used as probe. In addition, the β -actin
25 gene sequence (Cleveland et al. (1980) Cell 20:95-105) can be nick-translated and used as a control probe on duplicate filters to confirm the presence or absence of RNA on each blot and to provide a rough standard for use in quantitating differences in α - or β -specific mRNA
30 levels between cell lines. Typical northern and slot blot hybridization and wash conditions are as follows:

hybridization in 5x SSPE, 5X Denhardt's solution, 50% formamide, at 42°C followed by washing in 0.2x SSPE, 0.1% SDS, at 65°C.

B. Nicotine-binding assay

5 Cell lines generated by transfection with human neuronal nicotinic AChR α - or α - and β -subunit-encoding DNA can be analyzed for their ability to bind nicotine, for example, as compared to control cell lines: neuronally-derived cell lines PC12 (Boulter et al.,
10 (1986), supra; ATCC #CRL1721) and IMR32 (Clementi, et al. (1986); Int. J. Neurochem. 47:291-297; ATCC #CCL127), and muscle-derived cell line BC3H1 (Patrick, et al., (1977); J. Biol. Chem. 252:2143-2153). Negative control cells (i.e., host cells from which the transfectants were
15 prepared) are also included in the assay. The assay is conducted as follows:

Just prior to being assayed, transfected cells are removed from plates by scraping. Positive control cells used are PC12, BC3H1, and IMR32 (which had been
20 starved for fresh media for seven days). Control cell lines are removed by rinsing in 37°C assay buffer (50mM Tris/HCl, 1 mM MgCl₂, 2 mM CaCl₂, 120 mM NaCl, 3 mM EDTA, 2 mg/ml BSA and 0.1 % aprotinin at pH7.4). The cells are washed and resuspended to a concentration of $1 \times 10^6/250$
25 μ l. To each plastic assay tube is added 250 μ l of the cell solution, 15 nM ³H-nicotine, with or without 1 mM unlabeled nicotine, and assay buffer to make a final volume of 500 μ l. The assays for the transfected cell lines are incubated for 30 min at room temperature; the
30 assays of the positive control cells are incubated for 2 min at 1°C. After the appropriate incubation time, 450 μ l aliquots of assay volume are filtered through Whatman GF/C glass fiber filters which has been pretr ated by incubation in 0.05% polyethyleneimine for 24 hours at

4°C. The filters are then washed twice, with 4 ml each wash, with ice cold assay buffer. After washing, the filters are dried, added to vials containing 5 ml scintillation fluid and radioactivity is measured.

5 C. ⁸⁶Rb ion-flux assay

The ability of nicotine or nicotine agonists and antagonists to mediate the influx of ⁸⁶Rb into transfected and control cells has been found to provide an indication of the presence of functional AChRs on the
10 cell surface. The ⁸⁶Rb ion-flux assay is conducted as follows:

1. The night before the experiment, cells are plated at 2×10^6 per well (i.e., 2 ml per well) in a 6-well polylysine-coated plate.
- 15 2. The culture medium is decanted and the plate washed with 2 ml of assay buffer (50 mM HEPES, 260 mM sucrose, 5.4 mM KCl, 1.8 mM CaCl₂, 0.8 mM MgSO₄, 5.5 mM glucose) at room temperature.
3. The assay buffer is decanted and 1 ml of
20 assay buffer, containing 3 μ Ci/ml ⁸⁶Rb, with 5 mM ouabain and agonist or antagonist in a concentration to effect a maximum response, is added.
4. The plate is incubated on ice at 1°C for
4 min.
- 25 5. The buffer is decanted into a waste container and each well was washed with 3 ml of assay buffer, followed by two washes of 2 ml each.
6. The cells are lysed with 2 x 0.5 ml of
0.2% SDS per well and transferred to a scintillation vial
30 containing 5 ml of scintillation fluid.
7. The radioactivity contained in each vial is measured and the data calculated.

Positive control cells provided the following data in this assay:

63

| | | PC12 | | IMR32 | |
|-------------------|-----------------------------------|------------------|---------------------|------------------|---------------------|
| | | EC ₅₀ | Maximum response | EC ₅₀ | Maximum response |
| <u>Agonist</u> | | | | | |
| 5 | nicotine | 52 μ M | 2.1X ^a | 18 μ M | 7.7X ^a |
| | CCh [*] | 35 μ M | 3.3X ^b | 230 μ M | 7.6X ^c |
| | cytisine | 57 μ M | 3.6X ^d | 14 μ M | 10X ^e |
| <u>Antagonist</u> | | | | | |
| | d-tubocurarine | 0.81 μ M | | 2.5 μ M | |
| 10 | mecamylamine | 0.42 μ M | | 0.11 μ M | |
| | hexamethonium | nd ^f | | 22 μ M | |
| | atropine | 12.5 μ M | | 43 μ M | |
| 15 | * CCh = carbamylcholine | | | | |
| | ^a 200 μ M nicotine | | | | |
| | ^b 300 μ M CCh | | | | |
| | ^c 3mM CCh | | | | |
| | ^d 1mM cytisine | | | | |
| | ^e 100 μ M cytisine | | | | |
| 20 | ^f nd = not determined | | | | |

D. Electrophysiological Analysis of Mammalian Cells Transfected with Human Neuronal Nicotinic AChR Subunit-encoding DNA

Electrophysiological measurements may be used to assess the activity of recombinant receptors or to assess the ability of a test compound to potentiate, antagonize or otherwise modulate the magnitude and duration of the flow of cations through the ligand-gated recombinant AChR. The function of the expressed neuronal AChR can be assessed by a variety of electrophysiological techniques, including two-electrode voltage clamp and patch clamp methods. The cation-conducting channel intrinsic to the AChR opens in response to acetylcholine (ACh) or other nicotinic cholinergic agonists, permitting the flow of transmembrane current carried predominantly by sodium and potassium ions under physiological conditions. This current can be monitored directly by voltage clamp techniques. In preferred embodiments, transfected mammalian cells or injected oocytes are analyzed electrophysiologically for the presence of AChR agonist-dependent currents.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which
5 is described and claimed.

Summary of Sequences

Sequence ID No. 1 is a nucleotide sequence encoding an α_2 subunit of human neuronal nicotinic acetylcholine receptor.

10 Sequence ID No. 2 is the amino acid sequence deduced from the nucleotide sequence encoding an α_2 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 1.

15 Sequence ID No. 3 is a nucleotide sequence encoding an α_3 subunit of human neuronal nicotinic acetylcholine receptor.

20 Sequence ID No. 4 is the amino acid sequence deduced from the nucleotide sequence encoding an α_3 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 3.

 Sequence ID No. 5 is a nucleotide sequence encoding an α_4 subunit of a human neuronal nicotinic acetylcholine receptor.

25 Sequence ID No. 6 is the amino acid sequence deduced from the nucleotide sequence encoding an α_4 subunit of a human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 5.

Sequence ID No. 7 is a nucleotide sequence encoding an α_7 subunit of human neuronal nicotinic acetylcholine receptor.

5 Sequence ID No. 8 is the amino acid sequence deduced from the nucleotide sequence encoding an α_7 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 7.

10 Sequence ID No. 9 is a nucleotide sequence encoding a β_2 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 10 is the amino acid sequence deduced from the nucleotide sequence encoding a β_2 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 9.

15 Sequence ID No. 11 is a nucleotide sequence encoding a β_4 subunit of human neuronal nicotinic acetylcholine receptor.

20 Sequence ID No. 12 is the amino acid sequence deduced from the nucleotide sequence encoding a β_4 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 11.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Elliot, Kathryn J.
Ellis, Steven B.
Harpold, Michael M.

(ii) TITLE OF INVENTION: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE
RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
(B) STREET: 444 South Flower Street, Suite 2000
(C) CITY: Los Angeles
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 90071

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 08-MAR-1994
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/028,031
(B) FILING DATE: 08-MAR-1993

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Reiter, Stephen E.
(B) REGISTRATION NUMBER: 31,192
(C) REFERENCE/DOCKET NUMBER: FP41 9714

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 619-546-4737
(B) TELEFAX: 619-546-9392

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2277 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 166..1755

(D) OTHER INFORMATION: /product= "ALPHA-2 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|---|------|
| CAATGACCTG TTTTCTTCTG TAACCACAGG TTCGGTGGTG AGAGGAASCY TCGCAGAATC | 60 |
| CAGCAGAATC CTCACAGAAT CCAGCAGCAG CTCTGCTGGG GACATGGTCC ATGGTGCAAC | 120 |
| CCACAGCAAA GCCCTGACCT GACCTCCTGA TGCTCAGGAG AAGCCATGGG CCCCTCCTGT | 180 |
| CCTGTGTTCC TGTCTTCAC AAAGCTCAGC CTGTGGTGGC TCCTTCTGAC CCCAGCAGGT | 240 |
| GGAGAGGAAG CTAAGCGCCC ACCTCCCAGG GCTCCTGGAG ACCCACTCTC CTCTCCCAGT | 300 |
| CCCACGGCAT TGCCGCAGGG AGGCTCGCAT ACCGAGACTG AGGACCGGCT CTTCAAACAC | 360 |
| CTCTTCCGGG GCTACAACCG CTGGGCGCGC CCGGTGCCCA AACTTCAGA CGTGGTGATT | 420 |
| GTGCGCTTTG GACTGTCCAT CGCTCAGCTC ATCGATGTGG ATGAGAAGAA CCAAATGATG | 480 |
| ACCACCAACG TCTGGCTAAA ACAGGAGTGG AGCGACTACA AACTGCGCTG GAACCCCGCT | 540 |
| GATTTTGGCA ACATCACATC TCTCAGGGTC CTTCTGAGA TGATCTGGAT CCCCGACATT | 600 |
| GTTCTCTACA ACAATGCAGA TGGGGAGTTT GCAGTGACCC ACATGACCAA GGCCACCTC | 660 |
| TTCTCCACGG GCACTGTGCA CTGGGTGCCC CCGGCCATCT ACAAGAGCTC CTGCAGCATC | 720 |
| GACGTCACCT TCTTCCCCTT CGACCAGCAG AACTGCAAGA TGAAGTTTGG CTCCTGGACT | 780 |
| TATGACAAGG CCAAGATCGA CCTGGAGCAG ATGGAGCAGA CTGTGGACCT GAAGGACTAC | 840 |
| TGGGAGAGCG GCGAGTGGGC CATCGTCAAT GCCACGGGCA CCTACAACAG CAAGAAGTAC | 900 |
| GACTGCTGCG CCGAGATCTA CCCCAGCGTC ACCTAGGCCT TCGTCATCCG GCGGCTGCCG | 960 |
| CTCTTCTACA CCATCAACCT CATCATCCCC TGCCTGCTCA TCTCCTGCCT CACTGTGCTG | 1020 |
| GTCTTCTACC TGCCCTCCGA CTGCGGCGAG AAGATCACGC TGTGCATTTT GGTGCTGCTG | 1080 |
| TCACTCACCG TCTTCCTGCT GCTCATCACT GAGATCATCC CGTCCACCTC GCTGGTCATC | 1140 |
| CCGCTCATCG GCGAGTACCT GCTGTTCAAC ATGATCTTCG TCACCCTGTC CATCGTCATC | 1200 |
| ACCGTCTTCG TGCTCAATGT GCACCACCGC TCCCCAGCA CCCACACCAT GCCCCACTGG | 1260 |
| GTGCGGGGGG CCCTTCTGGG CTGTGTGCCC CGGTGGCTTC TGATGAACCG GCCCCACCA | 1320 |
| CCCGTGGAGC TCTGCCACCC CCTACGCCTG AAGCTCAGCC CCTCTTATCA CTGGCTGGAG | 1380 |
| AGCAACGTGG ATGCCGAGGA GAGGGAGGTG GTGGTGGAGG AGGAGGACAG ATGGGCATGT | 1440 |

68

```

GCAGGTCATG TGGCCCCCTC TGTGGGCACC CTCTGCAGCC ACGGCCACCT GCACTCTGGG 1500
GCCTCAGGTC CCAAGGCTGA GGCTCTGCTG CAGGAGGGTG AGCTGCTGCT ATCACCCCAC 1560
ATGCAGAAGG CACTGGAAGG TGTGCACTAC ATTGCCGACC ACCTGCGGTC TGAGGATGCT 1620
GACTCTTCGG TGAAGGAGGA CTGGAAGTAT GTTGCCATGG TCATCGACAG GATCTTCCTC 1680
TGGCTGTTTA TCATCGTCTG CTTCCTGGGG ACCATCGGCC TCTTTCTGCC TCCGTTCCCTA 1740
GCTGGAATGA TCTGACTGCA CCTCCCTCGA GCTGGCTCCC AGGGCAAAGG GGAGGGTTCT 1800
TGGATGTGGA AGGGCTTTGA ACAATGTTTA GATTTGGAGA TGAGCCCCAA GTGCCAGGGA 1860
GAACAGCCAG GTGAGGTGGG AGGTTGGAGA GCCAGGTGAG GTCTCTCTAA GTCAGGCTGG 1920
GGTTGAAGTT TGGAGTCTGT CCGAGTTTGC AGGGTGCTGA GCTGTATGGT CCAGCAGGGG 1980
AGTAATAAGG GCTCTTCCGG AAGGGGAGGA AGCGGGAGGC AGGGCCTGCA CCTGATGTGG 2040
AGGTACAGGG CAGATCTTCC CTACCGGGGA GGGATGGATG GTTGGATACA GGTGGCTGGG 2100
CTATTCCATC CATCTGGAAG CACATTTGAG CCTCCAGGCT TCTCCTTGAC GTCATTCTC 2160
TCCTTCCTTG CTCCAAAATG GCTCTGCACC AGCCGGCCCC CAGGAGGTCT GGCAGAGCTG 2220
AGAGCCATGG CCTGCAGGGG CTCCATATGT CCCTACGCGT GCAGCAGGCA AACAAGA 2277

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 529 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Gly Pro Ser Cys Pro Val Phe Leu Ser Phe Thr Lys Leu Ser Leu
1           5           10           15
Trp Trp Leu Leu Leu Thr Pro Ala Gly Gly Glu Glu Ala Lys Arg Pro
20           25           30
Pro Pro Arg Ala Pro Gly Asp Pro Leu Ser Ser Pro Ser Pro Thr Ala
35           40           45
Leu Pro Gln Gly Gly Ser His Thr Glu Thr Glu Asp Arg Leu Phe Lys
50           55           60
His Leu Phe Arg Gly Tyr Asn Arg Trp Ala Arg Pro Val Pro Asn Thr
65           70           75           80

```

69

Ser Asp Val Val Ile Val Arg Phe Gly Leu Ser Ile Ala Gln Leu Ile
 85 90 95
 Asp Val Asp Glu Lys Asn Gln Met Met Thr Thr Asn Val Trp Leu Lys
 100 105 110
 Gln Glu Trp Ser Asp Tyr Lys Leu Arg Trp Asn Pro Ala Asp Phe Gly
 115 120 125
 Asn Ile Thr Ser Leu Arg Val Pro Ser Glu Met Ile Trp Ile Pro Asp
 130 135 140
 Ile Val Leu Tyr Asn Asn Ala Asp Gly Glu Phe Ala Val Thr His Met
 145 150 155 160
 Thr Lys Ala His Leu Phe Ser Thr Gly Thr Val His Trp Val Pro Pro
 165 170 175
 Ala Ile Tyr Lys Ser Ser Cys Ser Ile Asp Val Thr Phe Phe Pro Phe
 180 185 190
 Asp Gln Gln Asn Cys Lys Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys
 195 200 205
 Ala Lys Ile Asp Leu Glu Gln Met Glu Gln Thr Val Asp Leu Lys Asp
 210 215 220
 Tyr Trp Glu Ser Gly Glu Trp Ala Ile Val Asn Ala Thr Gly Thr Tyr
 225 230 235 240
 Asn Ser Lys Lys Tyr Asp Cys Cys Ala Glu Ile Tyr Pro Asp Val Thr
 245 250 255
 Tyr Ala Phe Val Ile Arg Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu
 260 265 270
 Ile Ile Pro Cys Leu Leu Ile Ser Cys Leu Thr Val Leu Val Phe Tyr
 275 280 285
 Leu Pro Ser Asp Cys Gly Glu Lys Ile Thr Leu Cys Ile Ser Val Leu
 290 295 300
 Leu Ser Leu Thr Val Phe Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser
 305 310 315 320
 Thr Ser Leu Val Ile Pro Leu Ile Gly Glu Tyr Leu Leu Phe Thr Met
 325 330 335
 Ile Phe Val Thr Leu Ser Ile Val Ile Thr Val Phe Val Leu Asn Val
 340 345 350
 His His Arg Ser Pro Ser Thr His Thr Met Pro His Trp Val Arg Gly
 355 360 365
 Ala Leu Leu Gly Cys Val Pro Arg Trp Leu Leu Met Asn Arg Pro Pro
 370 375 380

70

Pro Pro Val Glu Leu Cys His Pro Leu Arg Leu Lys Leu Ser Pro Ser
 385 390 395 400
 Tyr His Trp Leu Glu Ser Asn Val Asp Ala Glu Glu Arg Glu Val Val
 405 410 415
 Val Glu Glu Glu Asp Arg Trp Ala Cys Ala Gly His Val Ala Pro Ser
 420 425 430
 Val Gly Thr Leu Cys Ser His Gly His Leu His Ser Gly Ala Ser Gly
 435 440 445
 Pro Lys Ala Glu Ala Leu Leu Gln Glu Gly Glu Leu Leu Leu Ser Pro
 450 455 460
 His Met Gln Lys Ala Leu Glu Gly Val His Tyr Ile Ala Asp His Leu
 465 470 475 480
 Arg Ser Glu Asp Ala Asp Ser Ser Val Lys Glu Asp Trp Lys Tyr Val
 485 490 495
 Ala Met Val Ile Asp Arg Ile Phe Leu Trp Leu Phe Ile Ile Val Cys
 500 505 510
 Phe Leu Gly Thr Ile Gly Leu Phe Leu Pro Pro Phe Leu Ala Gly Met
 515 520 525
 Ile

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1757 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 39..1553
- (D) OTHER INFORMATION: /product= "ALPHA-3 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGACCGTCC GGGTCCGCGG CCAGCCCGGC CACCAGCCAT GGGCTCTGGC CCGCTCTCGC 60
 TGCCCCTGGC GCTGTCGCCG CCGCGGCTGC TGCTGCTGCT GCTGTCTCTG CTGCCAGTGG 120
 CCAGGGCCTC AGAGGCTGAG CACCGTCTAT TTGAGCGGCT GTTTGAAGAT TACAATGAGA 180
 TCATCCGGCC TGTAGCCAAC GTGTCTGACC CAGTCATCAT CCATTTGAG GTGTCCATGT 240

| | |
|--|------|
| CTCAGCTGGT GAAGGTGGAT GAAGTAAACC AGATCATGGA GACCAACCTG TGGCTCAAGC | 300 |
| AAATCTGGAA TGA CTACAAG CTGAAGTGGA ACCCCTCTGA CTATGGTGGG GCAGACTTCA | 360 |
| TGCGTGTCCC TGCACAGAAG ATCTGGAAGC CAGACATTGT GCTGTATAAC AATGCTGTTG | 420 |
| GGGATTTCCA GGTGGACGAC AAGACCAAAG CCTTACTCAA GTACACTGGG GAGGTGACTT | 480 |
| GGATACCTCC GGCCATCTTT AAGAGCTCCT GTAAAATCGA CGTGACCTAC TTCCCGTTTG | 540 |
| ATTACCAAAA CTGTACCATG AAGTTCGGTT CCTGGTCCTA CGATAAGGCG AAAATCGATC | 600 |
| TGGTCCTGAT CGGCTCTTCC ATGAACCTCA AGGACTATTG GGAGAGCGGC GAGTGGGCCA | 660 |
| TCATCAAAGC CCCAGGCTAC AAACACGACA TCAAGTACAG CTGCTGCGAG GAGATCTACC | 720 |
| CCGACATCAC ATACTCGCTG WWCATCCGGC GGCTGTGCTT GTTCTACACC ATCAWCCTCA | 780 |
| TCATCCGCTG GCTGATCATC TCCTTCATCA CTGTGGTCGT CTCCTACCTG CCCTCCGACT | 840 |
| GCGGCGAGAA GGTGACCCTG TGYATTTCTG TCCTCCTCTC CCTGACGGTG TTTCTCCTGG | 900 |
| TGATCACTGA GACCATCCCT TCCACCTCGC TGGTCATCCC CCTGATTGGA GAGTACCTCC | 960 |
| TGWWCACCAT GATTTGTGTA ACCTTGTCCA TCGACATCAC CGTCTGCGTG CTCAACGTGC | 1020 |
| ACTACAGAAC CCCGACGACA CACACAATGC CCTCATGGGT GAAGACTGTA TTCTTGAMCC | 1080 |
| TGCTCCCCAG GGTGATGTWC ATGACCAGGC CAACAAGCAA CGAGGGCAAC GCTCAGAAGC | 1140 |
| CGAGGCCCCCT CTACGGTGCC GAGCTCTCAA ATCTGAATTG CTTAGCCGC GCAGAGTCCA | 1200 |
| AAGGCTGCAA GGAGGGCTAC CCCTGCCAGG ACGGGATGTG TGGTTACTGC CACCACCGCA | 1260 |
| GGATAAAAAT CTCCAATTTT AGTGCTAACC TCACGAGAAG CTCTAGTTCT GAATCTGTTG | 1320 |
| ATGCTGTGCT GTCCCTCTCT GCTTTGTAC CAGAAATCAA AGAAGCCATC CAAAGTGTC | 1380 |
| AGTATATTGC TGAAAATATG AAAGCACAAA ATGAAGCCAA AGAGATTCAA GATGATTGGA | 1440 |
| AGTATGTTGC CATGGTGATT GATCGTATTT TTCTGTGGGT TTTCACCCTG GTGTGCATTC | 1500 |
| TAGGGACAGC AGGATTGTTT CTGCAACCCC TGATGGCCAG GGAAGATGCA TAAGCACTAA | 1560 |
| GCTGTGTGCC TGCCTGGGAG ACTTCCTTGT GTCAGGGCAG GAGGAGGCTG CTTCTAGTA | 1620 |
| AGAACGTACT TTCTGTTATC AAGCTACCAG CTTTGTTHK GGCATTCGA GGTTTACTTA | 1680 |
| TTTTCCACTT ATCTTGGAAT CATGCCGCNN NNAAATGTCA AGAGTATTTA TTACCGATAA | 1740 |
| ATGAACATTT AACTAGC | 1757 |

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 504 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Gly Ser Gly Pro Leu Ser Leu Pro Leu Ala Leu Ser Pro Pro Arg
 1           5           10           15
Leu Leu Leu Leu Leu Leu Ser Leu Leu Pro Val Ala Arg Ala Ser Glu
 20           25           30
Ala Glu His Arg Leu Phe Glu Arg Leu Phe Glu Asp Tyr Asn Glu Ile
 35           40           45
Ile Arg Pro Val Ala Asn Val Ser Asp Pro Val Ile Ile His Phe Glu
 50           55           60
Val Ser Met Ser Gln Leu Val Lys Val Asp Glu Val Asn Gln Ile Met
 65           70           75           80
Glu Thr Asn Leu Trp Leu Lys Gln Ile Trp Asn Asp Tyr Lys Leu Lys
 85           90           95
Trp Asn Pro Ser Asp Tyr Gly Gly Ala Glu Phe Met Arg Val Pro Ala
 100          105          110
Gln Lys Ile Trp Lys Pro Asp Ile Val Leu Tyr Asn Asn Ala Val Gly
 115          120          125
Asp Phe Gln Val Asp Asp Lys Thr Lys Ala Leu Leu Lys Tyr Thr Gly
 130          135          140
Glu Val Thr Trp Ile Pro Pro Ala Ile Phe Lys Ser Ser Cys Lys Ile
 145          150          155          160
Asp Val Thr Tyr Phe Pro Phe Asp Tyr Gln Asn Cys Thr Met Lys Phe
 165          170          175
Gly Ser Trp Ser Tyr Asp Lys Ala Lys Ile Asp Leu Val Leu Ile Gly
 180          185          190
Ser Ser Met Asn Leu Lys Asp Tyr Trp Glu Ser Gly Glu Trp Ala Ile
 195          200          205
Ile Lys Ala Pro Gly Tyr Lys His Asp Ile Lys Tyr Ser Cys Cys Glu
 210          215          220

```

73

Glu Ile Tyr Pro Asp Ile Thr Tyr Ser Leu Xaa Ile Arg Arg Leu Ser
 225 230 235 240
 Leu Phe Tyr Thr Ile Xaa Leu Ile Ile Arg Trp Leu Ile Ile Ser Phe
 245 250 255
 Ile Thr Val Val Val Ser Tyr Leu Pro Ser Asp Cys Gly Glu Lys Val
 260 265 270
 Thr Leu Cys Ile Ser Val Leu Leu Ser Leu Thr Val Phe Leu Leu Val
 275 280 285
 Ile Thr Glu Thr Ile Pro Ser Thr Ser Leu Val Ile Pro Leu Ile Gly
 290 295 300
 Glu Tyr Leu Leu Xaa Thr Met Ile Cys Val Thr Leu Ser Ile Asp Ile
 305 310 315 320
 Thr Val Cys Val Leu Asn Val His Tyr Arg Thr Pro Thr Thr His Thr
 325 330 335
 Met Pro Ser Trp Val Lys Thr Val Phe Leu Xaa Leu Leu Pro Arg Val
 340 345 350
 Met Xaa Met Thr Arg Pro Thr Ser Asn Glu Gly Asn Ala Gln Lys Pro
 355 360 365
 Arg Pro Leu Tyr Gly Ala Glu Leu Ser Asn Leu Asn Cys Phe Ser Arg
 370 375 380
 Ala Glu Ser Lys Gly Cys Lys Glu Gly Tyr Pro Cys Gln Asp Gly Met
 385 390 395 400
 Cys Gly Tyr Cys His His Arg Arg Ile Lys Ile Ser Asn Phe Ser Ala
 405 410 415
 Asn Leu Thr Arg Ser Ser Ser Ser Glu Ser Val Asp Ala Val Leu Ser
 420 425 430
 Leu Ser Ala Leu Ser Pro Glu Ile Lys Glu Ala Ile Gln Ser Val Lys
 435 440 445
 Tyr Ile Ala Glu Asn Met Lys Ala Gln Asn Glu Ala Lys Glu Ile Gln
 450 455 460
 Asp Asp Trp Lys Tyr Val Ala Met Val Ile Asp Arg Ile Phe Leu Trp
 465 470 475 480
 Val Phe Thr Leu Val Cys Ile Leu Gly Thr Ala Gly Leu Phe Leu Gln
 485 490 495
 Pro Leu Met Ala Arg Glu Asp Ala
 500

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2363 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 173..2056
- (D) OTHER INFORMATION: /product= "ALPHA-4 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

| | |
|--|------|
| GCGCTCGCTG CGGCGCCGCC GCGGCNCCGC GCGCCACAGG AGAAGGCCAN CCGGGCCCCGG | 60 |
| CGGCCGAAGC GGCCCGCGAG GCGCGGGAGG CATGAAGTTG GGCGCGCACG GGCCTCGAAG | 120 |
| CGGCGGGGAG CCGGGAGCCG CCCGCATCTA GAGCCCGCGA GGTGCGTGCG CCATGGAGCT | 180 |
| AGGGGGCCCC GGAGCGCCGC GGCTGCTGCC GCGGCTGCTG CTGCTTCTGG GGACCGGCCT | 240 |
| CCTGCGCGCC AGCAGCCATG TGGAGACCCG GGCCCACGCC GAGGAGCGGC TCCTGAAGAA | 300 |
| ACTCTTCTCC GGTTACAACA AGTGGTCCCG ACCCGTGGCC AACATCTCGG ACGTGGTCCT | 360 |
| CGTCCGCTTC GGCCTGTCCA TCGCTCAGCT CATTGACGTG GATGAGAAGA ACCAGATGAT | 420 |
| GACCACGAAC GTCTGGGTGA AGCAGGAGTG GCACGACTAC AAGCTGCGCT GGGACCCAGC | 480 |
| TGACTATGAG AATGTCACCT CCATCCGCAT CCCCTCCGAG CTCATCTGGC GGCCGGACAT | 540 |
| CGCCCTCTAC AACAATGCTG ACGGGGACTT CGCGGCCACC CACCTGACCA AGGCCACCT | 600 |
| GTTCCATGAC GGGCGGGTGC AGCGGACTCC CCCGGCCATT TACAAGAGCT CCTGCAGCAT | 660 |
| CGACGTCACC TTCTTCCCCT TCGACCAGCA GAACTGCACC ATGAAATTGG GCTCCTGGAC | 720 |
| CTACGACAAG GCCAAGATCG ACCTGGTGAA CATGCACAGC CGCGTGGACC AGCTGGACTT | 780 |
| CTGGGAGAGT GGCGAGTGGC TCATCTCGGA CGCCGTGGGC ACCTACAACA CCAGGAAGTA | 840 |
| CGAGTGCTGC GCCGAGATCT ACCCGGACAT CACCTATGCC TACGCCATCC GGCGGCTGCC | 900 |
| GCTCTTCTAC ACCATCAACC TCATCATCCC CTGGCTGCTC ATCTCCTGCC TCACCGCGCT | 960 |
| GGTCTTCTAC CTGCCCTCCG AGTGTGGCGA GAAGATCACG CTGTGCATCT CCGTGCTGCT | 1020 |
| GTCGCTCACC GTCTTCCTGC TGCTCATCAC CGAGATCATC CCGTCCACCT CACTGGTCAT | 1080 |
| CCCACTCATC GGCGAGTACC TGCTGTTTAC CATGATCTTC GTCACCCTGT CCATCGCCAT | 1140 |

75

| | |
|--|------|
| CACGGTCTTC GTGCTCAACG TGCACCACCG CTCGCCACGC ACGCACACCA TGCCACCTG | 1200 |
| GGTACGCAGG GTCTTCCTGG ACATCGTGCC ACGCCTGCTC CTCATGAAGC GGCCGTCCGT | 1260 |
| GGTCAAGGAC AATTGCCGGC GGCTCATCGA GTCCATGCAT AAGATGGCCA GTGCCCCGCG | 1320 |
| CTTCTGGCCC GAGCCAGAAG GGGAGCCCCC TGCCACGAGC GGCACCCAGA GCCTGCACCC | 1380 |
| TCCCTCACCG TCCTTCTGCG TCCCCCTGGA TGTGCCGGCT GAGCCTGGGC CTTCTGCAA | 1440 |
| GTCACCCCTCC GACCAGCTCC CTCCTCAGCA GCCCCTGGAA GCTGAGAAAG CCAGCCCCCA | 1500 |
| CCCCTCGCCT GGACCCTGCC GCCCGCCCCA CGGCACCCAG GCACCAGGGC TGGCCAAAGC | 1560 |
| CAGGTCCCTC AGCGTCCAGC ACATGTCCAG CCCTGGCGAA GCGGTGGAAG GCGGCGTCCG | 1620 |
| GTGCCGGTCT CGGAGCATCC AGTACTGTGT TCCCCGAGAC GATGCCGCCC CCGAGGCAGA | 1680 |
| TGGCCAGGCT GCCGGCGCCC TGGCCTCTCG CAACAGCCAC TCGGCTGAGC TCCACCCCC | 1740 |
| AGACCAGCCC TCTCCGTGCA AATGCACATG CAAGAAGGAG CCCTCTTCGG TGTCCCCGAG | 1800 |
| CGCCACGGTC AAGACCCGCA GCACCAAAGC GCCGCCGCCG CACCTGCCCC TGTCGCCGGC | 1860 |
| CCTGAGCCGG GCGGTGGAGG GCGTCCAGTA CATTGCAGAC CACCTGAAGG CCGAAGACAC | 1920 |
| AGACTTCTCG GTGAAGGAGG ACTGGAAGTA CGTGGCCATG GTCATCGACC GCATCTTCCT | 1980 |
| CTGGATGTTT ATCATCGTCT GCCTGCTGGG GACGGTGGGC CTCTTCCTGC CGCCCTGGCT | 2040 |
| GGCTGGCATG ATCTAGGAAG GGACCGGGAG CCTGCGTGGC CTGGGGCTGC CGYGCACGGG | 2100 |
| GCCAGCATCC ATGCGGCCGG CCTGGGGCCG GGCTGGCTTC TCCCTGGACT CTGTGGGGCC | 2160 |
| ACACGTTTGC CAAATTTTCC TTCCTGTTCT GTGTCTGCTG TAAGACGGCC TTGGACGGCG | 2220 |
| ACACGGCCTC TGGGGAGACC GAGTGTGGAG CTGCTTCCAG TTGGACTCTS GCCTCAGNAG | 2280 |
| GCAGCGGCTT GGAGCAGAGG TGGCGGTCGC CGCCTYCTAC CTGCAGGACT CGGGCTAACT | 2340 |
| CCAGCTCTCC CCCTGCGCAG CCC | 2363 |

76

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 627 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Glu Leu Gly Gly Pro Gly Ala Pro Arg Leu Leu Pro Pro Leu Leu
 1           5           10           15
Leu Leu Leu Gly Thr Gly Leu Leu Arg Ala Ser Ser His Val Glu Thr
          20           25           30
Arg Ala His Ala Glu Glu Arg Leu Leu Lys Lys Leu Phe Ser Gly Tyr
          35           40           45
Asn Lys Trp Ser Arg Pro Val Ala Asn Ile Ser Asp Val Val Leu Val
 50           55           60
Arg Phe Gly Leu Ser Ile Ala Gln Leu Ile Asp Val Asp Glu Lys Asn
 65           70           75           80
Gln Met Met Thr Thr Asn Val Trp Val Lys Gln Glu Trp His Asp Tyr
          85           90           95
Lys Leu Arg Trp Asp Pro Ala Asp Tyr Glu Asn Val Thr Ser Ile Arg
          100          105          110
Ile Pro Ser Glu Leu Ile Trp Arg Pro Asp Ile Ala Leu Tyr Asn Asn
          115          120          125
Ala Asp Gly Asp Phe Ala Ala Thr His Leu Thr Lys Ala His Leu Phe
          130          135          140
His Asp Gly Arg Val Gln Arg Thr Pro Pro Ala Ile Tyr Lys Ser Ser
          145          150          155          160
Cys Ser Ile Asp Val Thr Phe Phe Pro Phe Asp Gln Gln Asn Cys Thr
          165          170          175
Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys Ala Lys Ile Asp Leu Val
          180          185          190
Asn Met His Ser Arg Val Asp Gln Leu Asp Phe Trp Glu Ser Gly Glu
          195          200          205
Trp Leu Ile Ser Asp Ala Val Gly Thr Tyr Asn Thr Arg Lys Tyr Glu
          210          215          220

```

77

Cys Cys Ala Glu Ile Tyr Pro Asp Ile Thr Tyr Ala Tyr Ala Ile Arg
 225 230 235 240
 Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu Ile Ile Pro Trp Leu Leu
 245 250 255
 Ile Ser Cys Leu Thr Ala Leu Val Phe Tyr Leu Pro Ser Glu Cys Gly
 260 265 270
 Glu Lys Ile Thr Leu Cys Ile Ser Val Leu Leu Ser Leu Thr Val Phe
 275 280 285
 Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser Thr Ser Leu Val Ile Pro
 290 295 300
 Leu Ile Gly Glu Tyr Leu Leu Phe Thr Met Ile Phe Val Thr Leu Ser
 305 310 315 320
 Ile Ala Ile Thr Val Phe Val Leu Asn Val His His Arg Ser Pro Arg
 325 330 335
 Thr His Thr Met Pro Thr Trp Val Arg Arg Val Phe Leu Asp Ile Val
 340 345 350
 Pro Arg Leu Leu Leu Met Lys Arg Pro Ser Val Val Lys Asp Asn Cys
 355 360 365
 Arg Arg Leu Ile Glu Ser Met His Lys Met Ala Ser Ala Pro Arg Phe
 370 375 380
 Trp Pro Glu Pro Glu Gly Glu Pro Pro Ala Thr Ser Gly Thr Gln Ser
 385 390 395 400
 Leu His Pro Pro Ser Pro Ser Phe Cys Val Pro Leu Asp Val Pro Ala
 405 410 415
 Glu Pro Gly Pro Ser Cys Lys Ser Pro Ser Asp Gln Leu Pro Pro Gln
 420 425 430
 Gln Pro Leu Glu Ala Glu Lys Ala Ser Pro His Pro Ser Pro Gly Pro
 435 440 445
 Cys Arg Pro Pro His Gly Thr Gln Ala Pro Gly Leu Ala Lys Ala Arg
 450 455 460
 Ser Leu Ser Val Gln His Met Ser Ser Pro Gly Glu Ala Val Glu Gly
 465 470 475 480
 Gly Val Arg Cys Arg Ser Arg Ser Ile Gln Tyr Cys Val Pro Arg Asp
 485 490 495
 Asp Ala Ala Pro Glu Ala Asp Gly Gln Ala Ala Gly Ala Leu Ala Ser
 500 505 510
 Arg Asn Ser His Ser Ala Glu Leu Pro Pro Pro Asp Gln Pro Ser Pro
 515 520 525

78

Cys Lys Cys Thr Cys Lys Lys Glu Pro Ser Ser Val Ser Pro Ser Ala
 530 535 540
 Thr Val Lys Thr Arg Ser Thr Lys Ala Pro Pro Pro His Leu Pro Leu
 545 550 555 560
 Ser Pro Ala Leu Ser Arg Ala Val Glu Gly Val Gln Tyr Ile Ala Asp
 565 570 575
 His Leu Lys Ala Glu Asp Thr Asp Phe Ser Val Lys Glu Asp Trp Lys
 580 585 590
 Tyr Val Ala Met Val Ile Asp Arg Ile Phe Leu Trp Met Phe Ile Ile
 595 600 605
 Val Cys Leu Leu Gly Thr Val Gly Leu Phe Leu Pro Pro Trp Leu Ala
 610 615 620
 Gly Met Ile
 625

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1876 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 73..1581
- (D) OTHER INFORMATION: /product= "ALPHA-7 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

| | |
|---|-----|
| GGCCGCAGGC GCAGGCCCGG GCGACAGCCG AGACGTGGAG CGCGCCGGCT CGCTGCAGCT | 60 |
| CCGGGACTCA ACATGCGCTG CTCGCCGGGA GGCCTCTGGC TGGCGCTGGC CGCGTCGCTC | 120 |
| CTGCACGTGT CCCTGCAAGG CGAGTTCAG AGGAAGCTTT ACAAGGAGCT GGTCAAGAAC | 180 |
| TACAATCCCT TGGAGAGGCC CGTGGCCAAT GACTCGCAAC CACTCACCGT CTACTTCTCC | 240 |
| CTGAGCCTCC TGCAGATCAT GGACGTGGAT GAGAAGAACC AAGTTTTAAC CACCAACATT | 300 |
| TGGCTGCAAA TGTCTTGGAC AGATCACTAT TTACAGTGGA ATGTGTCAGA ATATCCAGGG | 360 |
| GTGAAGACTG TTCGTTTCCC AGATGGCCAG ATTTGGAAAC CAGACATTCT TCTCTATAAC | 420 |
| AGTGCTGATG AGCGCTTTGA CGCCACATTC CACACTAACG TGTGTTGTA TTCTTCTGGG | 480 |

| | |
|---|------|
| CATTGCCAGT ACCTGCCTCC AGGCATATTC AAGAGTTCCT GCTACATCGA TGTACGCTGG | 540 |
| TTTCCCTTTG ATGTGCAGCA CTGCAAACTG AAGTTTGGGT CCTGGTCTTA CGGAGGCTGG | 600 |
| TCCTTGGATC TGCAGATGCA GGAGGCAGAT ATCAGTGGCT ATATCCCCAA TGGAGAATGG | 660 |
| GACCTAGTGG GAATCCCCGG CAAGAGGAGT GAAAGGTTCT ATGAGTGCTG CAAAGAGCCC | 720 |
| TACCCCGATG TCACCTTCAC AGTGACCATG CGCCGCAGGA CGCTCTACTA TGGCCTCAAC | 780 |
| CTGCTGATCC CCTGTGTGCT CATCTCGGCC CTCGCCCTGC TGGTGTTCCT GCTTCCTGCA | 840 |
| GATTCCGGGG AGAAGATTTC CCTGGGGATA ACAGTCTTAC TCTCTTTAC CGTCTTCATG | 900 |
| CTGCTCGTGG CTGAGATCAT GCCCGCAACA TCCGATTCCG TACCATTGAT AGCCCAGTAC | 960 |
| TTGCCCAGCA CCATGATCAT CGTGGGCCTC TCGGTGGTGG TGACGGTGAT CGTGCTGCAG | 1020 |
| TACCACCACC ACGACCCCGA CGGGGGCAAG ATGCCCAAGT GGACCAGAGT CATCCTTCTG | 1080 |
| AACTGGTGCG CGTGGTTCTT SCGAATGAAG AGGCCCGGGG AGGACAAGGT GCGCCCGGCC | 1140 |
| TGCCAGCACA AGCAGCGGCG CTGCAGCCTG GCCAGTGTGG AGATGAGCGC CGTGGCGCCG | 1200 |
| CGCCCCGCCA GCAACGGGAA CCTGCTGTAC ATCGGCTTCC GCGGCCTGGA CGGCGTGAC | 1260 |
| TGTGTCCCGA CCCCCGACTC TGGGGTAGTG TGTGGCCGCA TGGCCTGCTC CCCCACGCAC | 1320 |
| GATGAGCACC TCCTGCACGG CGGGCAACCC CCGGAGGGGG ACCCGGACTT GGCCAAGATC | 1380 |
| CTGGAGGAGG TCCGCTACAT TGCCAATCGC TTCCGCTGCC AGGACGAAAG CGAGGCGGTC | 1440 |
| TGCAGCGAGT GGAAGTTGCG CGCCTGTGTG GTGGACCGCC TGTGCCTCAT GGCCTTCTCG | 1500 |
| GTCTTCACCA TCATCTGCAC CATCGGCATC CTGATGTCCG CTCCCAACTT CGTGGAGGCC | 1560 |
| GTGTCCAAAG ACTTTGCGTA ACCACGCCTG GTTCTGTACA TGTGAAAAAC TCACAGATGG | 1620 |
| GCAAGGCCTT TGGCTTGGCG AGATTTGGGG GTGCTAATCC AGGACAGCAT TACACGCCAC | 1680 |
| AACTCCAGTG TTCCCTTCTG GCTGTCAGTC GTGTTGCTTA CGGTTTCTTT GTTACTTTAG | 1740 |
| GTAGTAGAAT CTCAGCACTT TGTTTCATAT TCTCAGATGG GCTGATAGAT ATCCTTGGCA | 1800 |
| CATCCGTACC ATCGGTCAGC AGGGCCACTG AGTAGTCATT TTGCCCATA GCCCACTGCC | 1860 |
| TGGAAGCCCC TTCGGA | 1876 |

80

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 502 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Met Arg Cys Ser Pro Gly Gly Val Trp Leu Ala Leu Ala Ala Ser Leu
 1             5             10             15
Leu His Val Ser Leu Gln Gly Glu Phe Gln Arg Lys Leu Tyr Lys Glu
          20             25             30
Leu Val Lys Asn Tyr Asn Pro Leu Glu Arg Pro Val Ala Asn Asp Ser
          35             40             45
Gln Pro Leu Thr Val Tyr Phe Ser Leu Ser Leu Leu Gln Ile Met Asp
          50             55             60
Val Asp Glu Lys Asn Gln Val Leu Thr Thr Asn Ile Trp Leu Gln Met
          65             70             75             80
Ser Trp Thr Asp His Tyr Leu Gln Trp Asn Val Ser Glu Tyr Pro Gly
          85             90             95
Val Lys Thr Val Arg Phe Pro Asp Gly Gln Ile Trp Lys Pro Asp Ile
          100            105            110
Leu Leu Tyr Asn Ser Ala Asp Glu Arg Phe Asp Ala Thr Phe His Thr
          115            120            125
Asn Val Leu Val Asn Ser Ser Gly His Cys Gln Tyr Leu Pro Pro Gly
          130            135            140
Ile Phe Lys Ser Ser Cys Tyr Ile Asp Val Arg Trp Phe Pro Phe Asp
          145            150            155            160
Val Gln His Cys Lys Leu Lys Phe Gly Ser Trp Ser Tyr Gly Gly Trp
          165            170            175
Ser Leu Asp Leu Gln Met Gln Glu Ala Asp Ile Ser Gly Tyr Ile Pro
          180            185            190
Asn Gly Glu Trp Asp Leu Val Gly Ile Pro Gly Lys Arg Ser Glu Arg
          195            200            205
Phe Tyr Glu Cys Cys Lys Glu Pro Tyr Pro Asp Val Thr Phe Thr Val
          210            215            220

```

81

Thr Met Arg Arg Arg Thr Leu Tyr Tyr Gly Leu Asn Leu Leu Ile Pro
 225 230 235 240
 Cys Val Leu Ile Ser Ala Leu Ala Leu Leu Val Phe Leu Leu Pro Ala
 245 250 255
 Asp Ser Gly Glu Lys Ile Ser Leu Gly Ile Thr Val Leu Leu Ser Leu
 260 265 270
 Thr Val Phe Met Leu Leu Val Ala Glu Ile Met Pro Ala Thr Ser Asp
 275 280 285
 Ser Val Pro Leu Ile Ala Gln Tyr Phe Ala Ser Thr Met Ile Ile Val
 290 295 300
 Gly Leu Ser Val Val Val Thr Val Ile Val Leu Gln Tyr His His His
 305 310 315 320
 Asp Pro Asp Gly Gly Lys Met Pro Lys Trp Thr Arg Val Ile Leu Leu
 325 330 335
 Asn Trp Cys Ala Trp Phe Leu Arg Met Lys Arg Pro Gly Glu Asp Lys
 340 345 350
 Val Arg Pro Ala Cys Gln His Lys Gln Arg Arg Cys Ser Leu Ala Ser
 355 360 365
 Val Glu Met Ser Ala Val Ala Pro Pro Pro Ala Ser Asn Gly Asn Leu
 370 375 380
 Leu Tyr Ile Gly Phe Arg Gly Leu Asp Gly Val His Cys Val Pro Thr
 385 390 395 400
 Pro Asp Ser Gly Val Val Cys Gly Arg Met Ala Cys Ser Pro Thr His
 405 410 415
 Asp Glu His Leu Leu His Gly Gly Gln Pro Pro Glu Gly Asp Pro Asp
 420 425 430
 Leu Ala Lys Ile Leu Glu Glu Val Arg Tyr Ile Ala Asn Arg Phe Arg
 435 440 445
 Cys Gln Asp Glu Ser Glu Ala Val Cys Ser Glu Trp Lys Phe Ala Ala
 450 455 460
 Cys Val Val Asp Arg Leu Cys Leu Met Ala Phe Ser Val Phe Thr Ile
 465 470 475 480
 Ile Cys Thr Ile Gly Ile Leu Met Ser Ala Pro Asn Phe Val Glu Ala
 485 490 495
 Val Ser Lys Asp Phe Ala
 500

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2448 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 265..1773
- (D) OTHER INFORMATION: /product= "BETA-2 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

| | |
|--|------|
| CTCCTCCCC TCACCGTCCC AATTGTATTC CCTGGAAGAG CAGCCGGAAG AGCCTCCGCC | 60 |
| TGCTCATACC AGGATAGGCA AGAAGCTGGT TTCTCCTCGC AGCCGGCTCC CTGAGGCCCA | 120 |
| GGAACCACCG CGGCGGCCGG CACCACCTGG ACCCAGCTCC AGGCGGGCGC GGCTTCAGCA | 180 |
| CCACGGACAG CGCCCCACCC GCGGCCCTCC CCGCGGCGGC GCGCTCCACC CCGTGTAGGC | 240 |
| GAGGCAGCGA GCTATGCCCG CGGCATGGCC CGGCGCTGCG GCGCGTGGC GCTGCTCCTT | 300 |
| GGCTTCGGCC TCCTCCGGCT GTGCTCAGGG GTGTGGGTA CGGATACAGA GGAGCGGCTG | 360 |
| TGAGGAGCATC TCCTGGATCC TTCCCGCTAC AACAAGCTTA TCCGCCCAGC CACCAATGGC | 420 |
| TCTGAGCTGG TGACAGTACA GCTTATGGTG TCACTGGCCC AGCTCATCAG TGTGCATGAG | 480 |
| CGGGAGCAGA TCATGACCAC CAATGTCTGG CTGACCCAGG AGTGGGAAGA TTATCGCCTC | 540 |
| ACCTGGAAGC CTGAAGAGTT TGACAACATG AAGAAAGTTC GGCTCCCTTC CAAACACATC | 600 |
| TGGCTCCCAG ATGTGGTCCT GTACAACAAT GCTGACGGCA TGTACGAGGT GTCCTTCTAT | 660 |
| TCCAATGCCG TGGTCTCCTA TGATGGCAGC ATCTTCTGGC TGCCGCCTGC CATCTACAAG | 720 |
| AGCGCATGCA AGATTGAAGT AAAGCACTTC CCATTGACC AGCAGAACTG CACCATGAAG | 780 |
| TTCCGTTCGT GGACCTACGA CCGCACAGAG ATCGACTTGG TGCTGAAGAG TGAGGTGGCC | 840 |
| AGCCTGGACG ACTTCACACC TAGTGGTGAG TGGGACATCG TGGCGCTGCC GGGCCGGCGC | 900 |
| AACGAGAACC CCGACGACTC TACGTACGTG GACATCACGT ATGACTTCAT CATTGCGCGC | 960 |
| AAGCCGCTCT TCTACACCAT CAACCTCATC ATCCCCTGTG TGCTCATCAC CTCGCTAGCC | 1020 |
| ATCCTTGTCT TCTACCTGCC ATCCGACTGT GCGGAGAAGA TGACGTTGTG CATCTCAGTG | 1080 |
| CTGCTGGCGC TCACGGTCTT CCTGCTGCTC ATCTCCAAGA TCGTGCCTCC CACCTCCCTC | 1140 |

| | |
|---|------|
| GACGTGCCGC TCGTCGGCAA GTACCTCATG TTCACCATGG TGCTTGTCAC CTTCTCCATC | 1200 |
| GTCACCAGCG TGTGCGTGCT CAACGTGCAC CACCGCTCGC CCACCACGCA CACCATGGCG | 1260 |
| CCCTGGGTGA AGGTGCTCTT CCTGGAGAAG CTGCCCCGCG TGCTCTTCAT GCAGCAGCCA | 1320 |
| CGCCATCATT GCGCCCGTCA GCGCCTGCGC CTGCGGCGAC GCCAGCGTGA GCGCGAGGGC | 1380 |
| GCTGGAGCCC TCTTCTTCG CGAAGCCCCA GGGGCCGACT CCTGCACGTG CTTCGTCAAC | 1440 |
| CGCGCGTCGG TGCAGGGGTT GGCCGGGGCC TTCGGGGCTG AGCCTGCACC AGTGGCGGGC | 1500 |
| CCCGGGCGCT CAGGGGAGCC GTGTGGCTGT GGCCTCCGGG AGGCGGTGGA CGGCGTGCGC | 1560 |
| TTCATCGCAG ACCACATGCG GAGCGAGGAC GATGACCAGA GCGTGAGTGA GGACTGGAAG | 1620 |
| TACGTCGCCA TGGTGATCGA CCGCCTCTTC CTCTGGATCT TTGTCTTTGT CTGTGTCTTT | 1680 |
| GGCACCATCG GCATGTTTCT GCAGCCTCTC TTCCAGAACT ACACCACCAC CACCTTCCTC | 1740 |
| CACTCAGACC ACTCAGCCCC CAGCTCCAAG TGAGGCCCTT CCTCATCTCC ATGCTCTTTC | 1800 |
| ACCCTGCCAC CCTCTGCTGC ACAGTAGTGT TGGGTGGAGG ATGGACGAGT GAGCTACCAG | 1860 |
| GAAGAGGGGC GCTGCCCCCA CAGATCCATC CTTTTGCTTC ATCTGGAGTC CCTCCTCCCC | 1920 |
| CAGGCCTCCA TCCACACACA GCAGCTCCAA CCTGGAGGCT GGACCAACTG CTTTGTTTTG | 1980 |
| GCTGCTCTCC ATCTCTTGTA CCAGCCCAGG CAATAGTGTT GAGGAGGGGA GCAAGGCTGC | 2040 |
| TAAGTGGAAG ACAGAGATGG CAGAGCCATC CACCCTGAGG AGTGACGGGC AAGGGGCCAG | 2100 |
| GAAGGGGACA GGATTGTCTG CTGCCTCCAA GTCATGGGAG AAGAGGGGTA TAGGACAAGG | 2160 |
| GGTGGAAGGG CAGGAGCTCA CACCGCACCG GGCTGGCCTG ACACAATGGT AGCTCTGAAG | 2220 |
| GGAGGGGAAG AGAGAGGCCT GGGTGTGACC TGACACCTGC CGCTGCTTGA GTGGACAGCA | 2280 |
| GCTGGACTGG GTGGGCCCCA CAGTGGTCAG CGATTCTGTC CAAGTAGGGT TTAGCCGGGC | 2340 |
| CCCATGGTCA CAGACCCCTG GGGGAGGCTT CCAGCTCACT CCCACAGCCC CTTGCTTCTA | 2400 |
| AGGGATCCAG AGACCTGCTC CAGATCCTCT TTCCCCACTG AAGAATTC | 2448 |

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 502 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

Met Ala Arg Arg Cys Gly Pro Val Ala Leu Leu Leu Gly Phe Gly Leu
 1           5           10           15
Leu Arg Leu Cys Ser Gly Val Trp Gly Thr Asp Thr Glu Glu Arg Leu
 20           25           30
Val Glu His Leu Leu Asp Pro Ser Arg Tyr Asn Lys Leu Ile Arg Pro
 35           40           45
Ala Thr Asn Gly Ser Glu Leu Val Thr Val Gln Leu Met Val Ser Leu
 50           55           60
Ala Gln Leu Ile Ser Val His Glu Arg Glu Gln Ile Met Thr Thr Asn
 65           70           75           80
Val Trp Leu Thr Gln Glu Trp Glu Asp Tyr Arg Leu Thr Trp Lys Pro
 85           90           95
Glu Glu Phe Asp Asn Met Lys Lys Val Arg Leu Pro Ser Lys His Ile
 100          105          110
Trp Leu Pro Asp Val Val Leu Tyr Asn Asn Ala Asp Gly Met Tyr Glu
 115          120          125
Val Ser Phe Tyr Ser Asn Ala Val Val Ser Tyr Asp Gly Ser Ile Phe
 130          135          140
Trp Leu Pro Pro Ala Ile Tyr Lys Ser Ala Cys Lys Ile Glu Val Lys
 145          150          155          160
His Phe Pro Phe Asp Gln Gln Asn Cys Thr Met Lys Phe Arg Ser Trp
 165          170          175
Thr Tyr Asp Arg Thr Glu Ile Asp Leu Val Leu Lys Ser Glu Val Ala
 180          185          190
Ser Leu Asp Asp Phe Thr Pro Ser Gly Glu Trp Asp Ile Val Ala Leu
 195          200          205
Pro Gly Arg Arg Asn Glu Asn Pro Asp Asp Ser Thr Tyr Val Asp Ile
 210          215          220

```

85

Thr Tyr Asp Phe Ile Ile Arg Arg Lys Pro Leu Phe Tyr Thr Ile Asn
 225 230 235 240
 Leu Ile Ile Pro Cys Val Leu Ile Thr Ser Leu Ala Ile Leu Val Phe
 245 250 255
 Tyr Leu Pro Ser Asp Cys Gly Glu Lys Met Thr Leu Cys Ile Ser Val
 260 265 270
 Leu Leu Ala Leu Thr Val Phe Leu Leu Leu Ile Ser Lys Ile Val Pro
 275 280 285
 Pro Thr Ser Leu Asp Val Pro Leu Val Gly Lys Tyr Leu Met Phe Thr
 290 295 300
 Met Val Leu Val Thr Phe Ser Ile Val Thr Ser Val Cys Val Leu Asn
 305 310 315 320
 Val His His Arg Ser Pro Thr Thr His Thr Met Ala Pro Trp Val Lys
 325 330 335
 Val Val Phe Leu Glu Lys Leu Pro Ala Leu Leu Phe Met Gln Gln Pro
 340 345 350
 Arg His His Cys Ala Arg Gln Arg Leu Arg Leu Arg Arg Arg Gln Arg
 355 360 365
 Glu Arg Glu Gly Ala Gly Ala Leu Phe Phe Arg Glu Ala Pro Gly Ala
 370 375 380
 Asp Ser Cys Thr Cys Phe Val Asn Arg Ala Ser Val Gln Gly Leu Ala
 385 390 395 400
 Gly Ala Phe Gly Ala Glu Pro Ala Pro Val Ala Gly Pro Gly Arg Ser
 405 410 415
 Gly Glu Pro Cys Gly Cys Gly Leu Arg Glu Ala Val Asp Gly Val Arg
 420 425 430
 Phe Ile Ala Asp His Met Arg Ser Glu Asp Asp Asp Gln Ser Val Ser
 435 440 445
 Glu Asp Trp Lys Tyr Val Ala Met Val Ile Asp Arg Leu Phe Leu Trp
 450 455 460
 Ile Phe Val Phe Val Cys Val Phe Gly Thr Ile Gly Met Phe Leu Gln
 465 470 475 480
 Pro Leu Phe Gln Asn Tyr Thr Thr Thr Thr Phe Leu His Ser Asp His
 485 490 495
 Ser Ala Pro Ser Ser Lys
 500

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1915 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 87..1583
- (D) OTHER INFORMATION: /product= "BETA-4 SUBUNIT"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

| | |
|--|------|
| CCGGCGCTCA CTCGACCGCG CGGCTCACGG GTGCCCTGTG ACCCCACAGC GGAGCTCGCG | 60 |
| GGGGCTGCCA CCCGGCCCCG CCGGCCATGA GGCGCGCGCC TTCCCTGGTC CTTTCTTCC | 120 |
| TGGTCGCCCT TTGCGGGCGC GGGAACTGCC GCGTGGCCAA TCGGGAGGAA AAGCTGATGG | 180 |
| ACGACCTTCT GAACAAAACC CGTTACAATA ACCTGATCCG CCCAGCCACC AGCTCCTCAC | 240 |
| AGCTCATCTC CATCAAGCTG CAGCTCTCCC TGGCCAGCT TATCAGCGTG AATGAGCGAG | 300 |
| AGCAGATCAT GACCACCAAT GTCTGGCTGA AACAGGAATG GACTGATTAC CGCCTGACCT | 360 |
| GGAACAGCTC CCGCTACGAG GGTGTGAACA TCCTGAGGAT CCCTGCAAAG CGCATCTGGT | 420 |
| TGCCTGACAT CGTGCTTTAC AACAAACGCCG ACGGGACCTA TGAGGTGTCT GTCTACACCA | 480 |
| ACTTGATAGT CCGGTCCAAC GGCAGCGTCC TGTGGCTGCC CCCTGCCATC TACAAGAGCG | 540 |
| CCTGCAAGAT TGAGGTGAAG TACTTTCCCT TCGACCAGCA GAACTGCACC CTCAAGTTCC | 600 |
| GCTCCTGGAC CTATGACCAC ACGGAGATAG ACATGGTCCT CATGACGCCC ACAGCCAGCA | 660 |
| TGGATGACTT TACTCCAGT GGTGAGTGGG ACATAGTGGC CCTCCCAGGG AGAAGGACAG | 720 |
| TGAACCCACA AGACCCAGC TACGTGGACG TGAATTACGA CTTTCATCATC AAGCGCAAGC | 780 |
| CTCTGTTCTA CACCATCAAC CTCATCATCC CCTGCGTGCT CACCACCTTG CTGGCCATCC | 840 |
| TCGTCTTCTA CCTGCCATCC GACTGCGGCG AGAAGATGAC ACTGTGCATC TCAGTGCTGC | 900 |
| TGGCACTGAC ATTCTTCCTG CTGCTCATCT CCAAGATCGT GCCACCCACC TCCCTCGATG | 960 |
| TGCCTCTCAT CGGCAAGTAC CTCATGTTCA CCATGGTGCT GGTACCTTC TCCATCGTCA | 1020 |
| CCAGCGTCTG TGTGCTCAAT GTGCACCACC GCTCGCCCAG CACCCACACC ATGGCACCCT | 1080 |
| GGGTCAAGCG CTGCTTCCTG CACAAGCTGC CTACCTTCCT CTTTCATGAAG CGCCCTGGCC | 1140 |

87

CCGACAGCAG CCCGGCCAGA GCCTTCCCCG CCAGCAAGTC ATGCGTGACC AAGCCCAGG 1200
 CCACCGCCAC CTCCACCAGC CCCTCCAAC TCTATGGGAA CTCCATGTAC TTTGTGAACC 1260
 CCGCCTCTGC AGCTTCCAAG TCTCCAGCCG GCTCTACCCC GGTGGCTATC CCCAGGGATT 1320
 TCTGGCTGCG GTCCTCTGGG AGGTTCCGAC AGGATGTGCA GGAGGCATTA GAAGGTGTCA 1380
 GCTTCATCGC CCAGCACATG AAGAATGACG ATGAAGACCA GAGTGTCTGT GAGGACTGGA 1440
 AGTACGTGGC TATGGTGGTG GACCGGCTGT TCCTGTGGGT GTTCATGTTT GTGTGCGTCC 1500
 TGGGCACTGT GGGGCTCTTC CTGCCGCCCC TCTTCAGAC CCATGCAGCT TCTGAGGGGC 1560
 CCTACGCTGC CCAGCGTGAC TGAGGGCCCC CTGGGTGTG GGGTGAGAGG ATGTGAGTGG 1620
 CCGGGTGGGC ACTTTGCTGC TTCTTTCTGG GTTGTGGCCG ATGAGGCCCT AAGTAAATAT 1680
 GTGAGCATTG GCCATCAACC CCATCAAACC AGCCACAGCC GTGGAACAGG CAAGGATGGG 1740
 GGCCTGGCCT GTCCTCTCTG AATGCCTTGG AGGGATCCCA GGAAGCCCCA GTAGGAGGGA 1800
 GCTTCAGACA GTTCAATTCT GGCCTGTCTT CCTTCCCTGC ACCGGGCAAT GGGGATAAAG 1860
 ATGACTTCGT AGCAGCACCT ACTATGCTTC AGGCATGGTG CCGGCCTGCC TCTCC 1915

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 498 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Arg Arg Ala Pro Ser Leu Val Leu Phe Phe Leu Val Ala Leu Cys
 1 5 10 15
 Gly Arg Gly Asn Cys Arg Val Ala Asn Ala Glu Glu Lys Leu Met Asp
 20 25 30
 Asp Leu Leu Asn Lys Thr Arg Tyr Asn Asn Leu Ile Arg Pro Ala Thr
 35 40 45
 Ser Ser Ser Gln Leu Ile Ser Ile Lys Leu Gln Leu Ser Leu Ala Gln
 50 55 60
 Leu Ile Ser Val Asn Glu Arg Glu Gln Ile Met Thr Thr Asn Val Trp
 65 70 75 80
 Leu Lys Gln Glu Trp Thr Asp Tyr Arg Leu Thr Trp Asn Ser Ser Arg
 85 90 95

88

Tyr Glu Gly Val Asn Ile Leu Arg Ile Pro Ala Lys Arg Ile Trp Leu
 100 105 110
 Pro Asp Ile Val Leu Tyr Asn Asn Ala Asp Gly Thr Tyr Glu Val Ser
 115 120 125
 Val Tyr Thr Asn Leu Ile Val Arg Ser Asn Gly Ser Val Leu Trp Leu
 130 135 140
 Pro Pro Ala Ile Tyr Lys Ser Ala Cys Lys Ile Glu Val Lys Tyr Phe
 145 150 155 160
 Pro Phe Asp Gln Gln Asn Cys Thr Leu Lys Phe Arg Ser Trp Thr Tyr
 165 170 175
 Asp His Thr Glu Ile Asp Met Val Leu Met Thr Pro Thr Ala Ser Met
 180 185 190
 Asp Asp Phe Thr Pro Ser Gly Glu Trp Asp Ile Val Ala Leu Pro Gly
 195 200 205
 Arg Arg Thr Val Asn Pro Gln Asp Pro Ser Tyr Val Asp Val Thr Tyr
 210 215 220
 Asp Phe Ile Ile Lys Arg Lys Pro Leu Phe Tyr Thr Ile Asn Leu Ile
 225 230 235 240
 Ile Pro Cys Val Leu Thr Thr Leu Leu Ala Ile Leu Val Phe Tyr Leu
 245 250 255
 Pro Ser Asp Cys Gly Glu Lys Met Thr Leu Cys Ile Ser Val Leu Leu
 260 265 270
 Ala Leu Thr Phe Phe Leu Leu Leu Ile Ser Lys Ile Val Pro Pro Thr
 275 280 285
 Ser Leu Asp Val Pro Leu Ile Gly Lys Tyr Leu Met Phe Thr Met Val
 290 295 300
 Leu Val Thr Phe Ser Ile Val Thr Ser Val Cys Val Leu Asn Val His
 305 310 315 320
 His Arg Ser Pro Ser Thr His Thr Met Ala Pro Trp Val Lys Arg Cys
 325 330 335
 Phe Leu His Lys Leu Pro Thr Phe Leu Phe Met Lys Arg Pro Gly Pro
 340 345 350
 Asp Ser Ser Pro Ala Arg Ala Phe Pro Pro Ser Lys Ser Cys Val Thr
 355 360 365
 Lys Pro Glu Ala Thr Ala Thr Ser Thr Ser Pro Ser Asn Phe Tyr Gly
 370 375 380
 Asn Ser Met Tyr Phe Val Asn Pro Ala Ser Ala Ala Ser Lys Ser Pro
 385 390 395 400

89

Ala Gly Ser Thr Pro Val Ala Ile Pro Arg Asp Phe Trp Leu Arg Ser
405 410 415

Ser Gly Arg Phe Arg Gln Asp Val Gln Glu Ala Leu Glu Gly Val Ser
420 425 430

Phe Ile Ala Gln His Met Lys Asn Asp Asp Glu Asp Gln Ser Val Val
435 440 445

Glu Asp Trp Lys Tyr Val Ala Met Val Val Asp Arg Leu Phe Leu Trp
450 455 460

Val Phe Met Phe Val Cys Val Leu Gly Thr Val Gly Leu Phe Leu Pro
465 470 475 480

Pro Leu Phe Gln Thr His Ala Ala Ser Glu Gly Pro Tyr Ala Ala Gln
485 490 495

Arg Asp

THAT WHICH IS CLAIMED:

1. Isolated DNA comprising a sequence of nucleotides encoding an α_4 or α_7 subunit of a human neuronal nicotinic acetylcholine receptor.

2. DNA according to claim 1 wherein the subunit is an α_4 subunit.

3. DNA according to claim 2 wherein said DNA encodes:

the amino acid sequence set forth in SEQ ID No:6, or

5

the amino acid sequence encoded by clone

HnAChR α 4.2 (ATCC Accession No. 69239), or

the 5' nucleotides of said DNA encode the amino acid sequence encoded by clone HnAChR α 4.1 (ATCC Accession No. 69152).

4. DNA according to claim 2 wherein said DNA hybridizes:

to substantially the entire coding sequence (nucleotides 173-2056) set forth in SEQ ID No:5 under high stringency conditions, or

5

under high stringency conditions to

substantially the entire sequence of the α_4 -encoding insert of clone HnAChR α 4.2 (ATCC Accession No. 69239), or

10

the 5' nucleotides of said DNA hybridize under high stringency conditions to the sequence of the α_4 -encoding insert of clone HnAChR α 4.1 (ATCC Accession No. 69152).

5. DNA according to claim 2 where in said DNA has substantially the same nucleotide sequence as:

nucleotides 173-2056 set forth in SEQ ID No:5,
or

5 the α_4 -encoding insert of clone HnAChR α 4.2 (ATCC Accession No. 69239), or

the 5' nucleotides of said DNA have substantially the same sequence as the α_4 -encoding insert of clone HnAChR α 4.1 (ATCC Accession No. 69152).

10

6. DNA according to claim 1 wherein the subunit is an α_7 subunit.

7. DNA according to claim 6 wherein the nucleotides of said DNA encodes the amino acid sequence set forth in SEQ ID No:8.

8. DNA according to claim 6 wherein the nucleotides of said DNA hybridize under high stringency conditions to substantially the entire coding sequence (nucleotides 73-1581) set forth in SEQ ID No:7.

9. DNA according to claim 6 wherein the nucleotides of said DNA have substantially the same nucleotide sequence as nucleotides 73-1581 set forth in SEQ ID No:7.

10. Isolated DNA comprising nucleotides encoding a β_4 subunit of a human neuronal nicotinic acetylcholine receptor.

11. DNA according to claim 10 wherein the nucleotides of said DNA encode the amino acid sequence set forth in SEQ ID No:12.

12. DNA according to claim 10 wherein the nucleotides of said DNA hybridize under high stringency conditions to substantially the entire coding sequence (nucleotides 87-1583) set forth in SEQ ID No:11.

13. DNA according to claim 10 wherein the nucleotides of said DNA have substantially the same nucleotide sequence as nucleotides 87-1583 set forth in SEQ ID No:11.

14. Cells containing at least one DNA according to claim 1, wherein said cells are bacterial cells, eukaryotic cells or amphibian oöcytes.

15. Cells according to claim 14, further containing at least one DNA encoding a β subunit of human neuronal nicotinic acetylcholine receptor.

16. Cells according to claim 15 further characterized as being capable of expressing voltage dependent calcium channels.

17. Cells according to claim 15 wherein said β subunit is selected from β_2 or β_4 .

18. Cells according to claim 15 wherein said β subunit is β_4 .

19. Cells according to claim 14 wherein said cells express functional neuronal nicotinic acetylcholine receptors that contain one or more subunits encoded by said DNA.

20. Cells containing at least one DNA according to claim 10, wherein said cells are bacterial cells, eukaryotic cells or amphibian oöcytes.

21. Cells according to claim 20, further containing at least one DNA encoding an α subunit of human neuronal nicotinic acetylcholine receptor.

22. Cells according to claim 21 further characterized as being capable of expressing voltage dependent calcium channels.

23. Cells according to claim 21 wherein said α subunit is selected from α_1 , α_2 , α_3 , α_4 , α_5 or α_7 .

24. Cells according to claim 21 wherein said α subunit is selected from α_4 or α_7 .

25. Cells according to claim 21, containing DNA encoding human α_3 and human β_4 subunits.

26. Cells according to claim 20 wherein said cells express functional neuronal nicotinic acetylcholine receptors that contain one or more subunits encoded by said DNA.

27. A method of screening compounds to identify compounds which modulate the activity of human neuronal nicotinic acetylcholine receptors, said method comprising determining the effect of a compound on the neuronal nicotinic acetylcholine receptor activity in test cells according to claim 15, compared to the effect on control cells or to the neuronal nicotinic acetylcholine receptor activity of the cells in the absence of the compound,

wherein control cells are substantially identical to the test cells, but control cells do not express nicotinic acetylcholine receptors.

28. A method of screening compounds to identify compounds which modulate the activity of human neuronal nicotinic acetylcholine receptors, said method comprising determining the effect of a compound on the neuronal nicotinic acetylcholine receptor activity in test cells according to claim 21, compared to the effect on control cells or to the neuronal nicotinic acetylcholine receptor activity of the cells in the absence of the compound,
- wherein control cells are substantially identical to the test cells, but control cells do not express nicotinic acetylcholine receptors.

29. A recombinant human neuronal nicotinic acetylcholine receptor subunit selected from an α_4 or α_7 subunit.

30. A recombinant human neuronal nicotinic acetylcholine receptor comprising one or more of the subunits of claim 29.

31. Human neuronal nicotinic acetylcholine receptor according to claim 30, further comprising at least one human neuronal nicotinic acetylcholine receptor beta subunit.

32. Recombinant human neuronal nicotinic acetylcholine receptor β_4 subunit.

33. A recombinant human neuronal nicotinic acetylcholine receptor comprising the subunit of claim 32.

34. Human neuronal nicotinic acetylcholine receptor according to claim 33, further comprising at least one human neuronal nicotinic acetylcholine receptor alpha subunit.

35. A method for identifying functional neuronal nicotinic acetylcholine receptor subunits and combinations thereof, said method comprising:

- (a) introducing at least one DNA according to
5 claim 1, or RNA complementary thereto, and optionally DNA encoding at least one beta subunit of a human neuronal nicotinic acetylcholine receptor, or RNA complementary thereto, into eukaryotic cells; and
- (b) assaying for neuronal nicotinic
10 acetylcholine receptor activity in cells of step (a), wherein the activity is mediated by a receptor containing one or more of the subunits encoded by said introduced DNA.

36. A method for identifying functional neuronal nicotinic acetylcholine receptor subunits and combinations thereof, said method comprising:

- (a) introducing at least one DNA according to
5 claim 10, or RNA complementary thereto, and DNA encoding at least one alpha subunit of a neuronal nicotinic acetylcholine receptor, or RNA complementary thereto, into eukaryotic cells; and
- (b) assaying for neuronal nicotinic
10 acetylcholine receptor activity in cells of step (a), wherein the activity is mediated by a receptor containing one or more of the subunits encoded by said introduced DNA.

37. Isolated mRNA encoded by the DNA of Claim 1.

38. Isolated mRNA encoded by the DNA of Claim 10.

39. Cells containing mRNA according to claim 37.

40. Cells containing mRNA according to claim 38.


41. Cells according to claim 39 wherein said cells further contain mRNA encoding a beta subunit of a human neuronal nicotinic acetylcholine receptor.

42. Cells according to claim 40 wherein said cells further contain mRNA encoding an alpha subunit of a human neuronal nicotinic acetylcholine receptor.

43. An antibody generated against the protein of claim 29 or an immuogenic portion thereof.

44. An antibody generated against the protein of claim 32 or an immuogenic portion thereof.

FIGURE 1



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

C12N 15/12, 5/10, C12Q 1/68, C07K
13/00, G01N 33/68, C12P 21/08

A3

(11) International Publication Number:

WO 94/20617

(43) International Publication Date: 15 September 1994 (15.09.94)

(21) International Application Number: PCT/US94/02447

(22) International Filing Date: 8 March 1994 (08.03.94)

(30) Priority Data:

08/028,031

8 March 1993 (08.03.93)

US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

08/028,031 (CIP)

8 March 1993 (08.03.93)

(71) Applicant (for all designated States except US): THE SALK
INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSO-
CIATES, INCORPORATED [US/US]; Suite 300, 505
Coast Boulevard South, La Jolla, CA 92037-4641 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ELLIOTT, Kathryn, J.
[US/US]; 3854 Baker Street, San Diego, CA 92117 (US).
ELLIS, Steven, B. [US/US]; 8939 Oviedo Street, San Diego,
92129 (US). HARPOLD, Michael, M. [US/US]; 15630
Creek Hills Road, El Cajon, CA 92021 (US).(74) Agent: REITER, Stephen, E.; Pretty, Schroeder, Brueggemann
& Clark, Suite 2000, 444 South Flower Street, Los Angeles,
CA 90071 (US).(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN,
CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ,
LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT,
RO, RU, SD, SE, SI, SK, TJ, UA, US, UZ, VN, European
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.


(88) Date of publication of the international search report:

27 October 1994 (27.10.94)

(54) Title: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR COMPOSITIONS AND METHODS EMPLOYING
SAME

(57) Abstract

Nucleic acids encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing said nucleic acids, methods for producing alpha and beta subunits and recombinant (i.e., isolated or substantially pure) alpha subunits (specifically α_4 and α_7) and beta subunits (specifically β_4) are provided. In addition, combinations of subunits (i.e., α_1 , α_2 , α_3 , α_4 , and/or α_7 subunits in combination with β_4 subunits; or β_2 , β_3 and/or β_4 subunits in combination with α_4 and/or α_7 subunits) are provided.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | CN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TC | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12N15/12 C07K13/00 C12N5/10 G01N33/68 C12Q1/68
C12P21/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N C07K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| P, X | SOCIETY FOR NEUROSCIENCE ABSTRACTS vol. 19, no. 1-3, November 1993 page 69 ELLIOTT K; URRUTIA A; JOHNSON E; WILLIAMS M E; ELLIS S B; VELICELEBI G; HARPOLD M M; 'Cloning and functional expression of human neuronal nicotinic acetylcholine receptor subunit alpha-2, alpha-3, alpha-4, alpha-7, beta-2 and beta-4' & 23rd Annual Meeting of the Society for Neuroscience, Washington, D.C., USA, November 7-12, 1993. See the Abstract --- | 1-44 |
| X | WO, A, 90 10648 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, US) 20 September 1990 see the whole document --- -/-- | 1-3, 10, 12, 14-44 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 August 1994

Date of mailing of the international search report

05. 09. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Nauche, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/02447

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|---|
| X | THE JOURNAL OF NEUROSCIENCE vol. 13, no. 2 , February 1993 pages 596 - 604 SÉGUÉLA, P. ET AL. 'Molecular cloning, functional properties, and distribution of rat brain alpha 7 : a nicotinic cation channel highly permeable to calcium' see the whole document --- | 1,5,6,8, 9,14, 20-24, 29,35, 37,39, 40,42,43 |
| X | FEBS LETTERS. vol. 312, no. 1 , November 1992 , AMSTERDAM NL pages 66 - 70 TARRONI, P. ET AL.; 'Neuronal-type nicotinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines' see the whole document --- | 10-14, 20-23, 25,26, 32-34, 38, 40-42,44 |
| A | WO,A,91 15602 (THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC.; US) 17 October 1991 see the whole document ----- | 1-44 |

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|---|---------------------|----------------------------|---------|---------------------|
| WO-A-9010648 | 20-09-90 | EP-A- | 0463064 | 02-01-92 |
| | | JP-T- | 4504123 | 23-07-92 |
| ----- | | | | |
| WO-A-9115602 | 17-10-91 | EP-A- | 0523187 | 20-01-93 |
| ----- | | | | |